

Europäisches **Patentamt**

European **Patent Office** Office eur des brevets

EPO4/1304

REC'D 1:0 MAY 2004 PCT **WIPO**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application conformes à la version described on the following page, as originally filed.

Les documents fixés à cette attestation sont initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patent application No. Demande de brevet n° Patentanmeldung Nr.

03003394.8

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;

For the President of the European Patent Office

Le Président de l'Office européen des brevets

R C van Dijk

BEST AVAILABLE COPY



European **Patent Office**

Office européen des brevets

Anmeldung Nr:

Application no.:

03003394.8

Demande no:

Anmeldetag:

Date of filing:

14.02.03

Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Ferring B.V. Polaris Avenue 144 2132 JX Hoofddorp PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention: (Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung. If no title is shown please refer to the description. Si aucun titre n'est indiqué se referer à la description.)

Oxytocin agonists and vasopressin antagonists


In Anspruch genommene Prioriät(en) / Priority(ies) claimed /Priorité(s) revendiquée(s) Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/ Classification internationale des brevets:

C07D/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of. filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR LI



OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates to novel non-peptide oxytocin agonists and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of non-peptide oxytocin agonists for the treatment of certain physiological disorders, such as erectile dysfunction and primary dysmenorrhoea.

BACKGROUND

Neurophyseal hormones

The neurophyseal hormones oxytocin (OT) and vasopressin (VP) are cyclic nonapeptides secreted by the posterior pituitary gland. The structure of oxytocin is shown below.

Oxytocin - cyclo^{1,6}-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂

Vasopressin-differs from oxytocin in that it has phenylalanine at position 3 in place of isoleucine and arginine at position 8 in place of leucine. Both hormones are synthesised in vivo as larger precursors, neurophysins, which are subject to post-translational processing to release the mature peptides. OT and VP act through a family of heptahelical receptors. Only one OT receptor has so far been well characterised, while three VP receptors are known. These are designated the V_{fa}, V_{1b} and V₂ receptors.

Applications over he read to 1962.

Empfansszeit 14 Peb. 16:14

~ ~

20

The first target organs to be identified for OT were the uterus, where it is implicated in the onset and progress of labour, and mammary glands, where it is involved in the regulation of milk expression. Other organs also express OT receptors, and it is clear that OT has a range of physiological roles that have not been fully elaborated yet. In particular, it has been suggested that OT acting in the CNS is involved in the erectile response in males, and in the regulation of female sexual arousal. For example, OT is erectogenic when administered i.c.v. to male rats. It also has erectogenic activity when given i.v., but the doses required are up to two orders of magnitude greater, which is consistent with a central mode of action.

Vasopressin acts on the blood vessels, where it is a potent vasoconstrictor, and on the kidneys, where it promotes water reuptake leading to an antidiuretic effect.

15 Oxytocin agonists and antagonists

A number of peptide analogues of OT are known in the literature. These include both agonists and antagonists. OT and its agonists are used, for example, to accelerate labour and to increase uterine muscle tone to control post-partum bleeding, and one antagonist, atosiban, has recently been registered as a treatment for pre-term labour. However, the peptidic nature of these compounds means that they are not likely to be bioavailable after oral dosing or to cross efficiently into the CNS. In order to get drugs that can be given orally and to be able to exploit the central effects of OT, attention has increasingly turned to non-peptides. As a result, there are many publications describing non-peptide OT antagonists in early-stage development. So far, however, there have been no reports of non-peptide OT agonists. This is not unexpected, as it is generally held that it is easier to find a receptor antagonist than an agonist.

So there remains a need for non-peptide OT receptor agonists. Such compounds should preferably be selective for the OT receptor over the VP receptors. They could be expected to show therapeutic utility in male and female sexual dysfunction, particularly male erectile dysfunction, in promoting labour, in controlling post-partum bleeding, in increasing milk let-down as well as a number of other indications.

TOTAL DE LE LICHA COMO RECEISO DE RESCOPEL CREACTET DE ALS OSCIALISTES DE LE ARREST MONTESE APPLICATIONS DE LE FERENCIA DE L'ARREST MONTESE.

The V_{1a} receptor is normally acted upon by the endogenous agonist ligand, arginine vasopressin (AVP). AVP also acts on the V_{1b} and V_2 receptors. It exerts a variety of biological effects in mammals including regulation of water and solute excretion by the kidney. AVP is structurally related to OT.

The V_{1a}, V_{1b}, and V₂, as well as the OT receptors, are members of the super-family of seven transmembrane receptors known as G-protein coupled receptors. The V_{1a} receptor mediates phospholipase C activation and intracellular calcium mobilisation. Localisation of the receptors includes blood platelets, blood vessels, hepatocytes, brain and uterus-cervix. Thus a V_{1a} antagonist may have effects on any or all of these tissues. For example, selective V_{1a} antagonists have been cited as having clinical utility in primary dysmenor-rhoca, pre-term labour, hypertension, Raynauld's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.

With respect to primary dysmenorrhoea it has been proposed that myometrial activity is markedly increased in women with primary dysmenorrhoea during menstruation. It is proposed that the myometrial ischemia caused by increased uterine contractility might explain the menstrual pain. Furthermore, on the first day of menstruation, higher plasma concentrations of vasopressin have been measured in dysmenorrhoeal women than in controls.

In healthy women without dysmenorrhoea, intravenous infusion of lysine-vasopressin resulted in decreased uterine blood flow, increased uterine contractility and slight to moderate like-like pain, these effects being inhibited by a selective human V_{1a} receptor antagonist. (Bossmar T; Brouard R; Doberl A; Akerlund M, Department of Obstetrics and Gynaecology, University Hospital of Lund, Sweden BRITISH JOURNAL OF OBSTETRICS AND GYNAE-COLOGY (1997 Apr.), 104(4), 471-7.). Also, it is known that vasopressin contracts human uterine arteries in a dose-dependent and V_{1a} -mediated fashion.

The above evidence suggests that a V_{1a} antagonist would be an appropriate and effective treatment for primary dysmenorrhoea. Further evidence is taken from the clinical study carried out on the selective V_{1a} antagonist SR49059 ("Effect of SR49059, an orally active V_{1a} vasopressin receptor antagonist, in the prevention of dysmenorrhea". Brouard, R.; Bossmar, T.; Fournie-Lloret, D. Chassard, D. Akerbred, M. G., G. S.; Bossmar, T.;

Fournie-Llore, D.; Chassard, D.; Akerlund, M. Sanofi Recherche, Clinical Development, Paris, Fr. BJOG (2000), 107(5), 614-619.). It was found that

2003 OF 14 to 48 5 Mg Smart rationally applyed proceedings of the Mrs. Sept. 11 Mrs. Submitted to 2114 (Submitted Only Submitted Only Submitt

Empfansszeit 14. Reb. 16:14

20

10

there was a dose-related decrease in pain and a dose-related decrease in the amount of additional pain-killer taken compared to patients taking placebo.

SUMMARY OF THE INVENTION

The present invention is based on a series of potent and specific OT receptor agonists (herein also called OT agonists) and/or VP receptor antagonists (herein also called VP antagonists) according to general formula 1:

$$R^{1}$$
 R^{2}
 R^{2}
 R^{1}
 R^{2}
 R^{2

1

wherein G1 is a group according to general formula 2, 3, 4, 5, 6 or 7:

wherein
$$G$$
 is a group according to goldon A^{3}
 A^{4}
 A^{5}
 A^{4}
 A^{5}
 A^{6}
 A^{7}
 A^{7}
 A^{6}
 A^{7}
 $A^{$

wherein:

- 10 A¹ is CH₂, CH(OH), NH, N-alkyl, O or S;
 - A² is CH₂, CH(OH), C(=O) or NH;
 - A3 is S, NH, N-alkyl, -CH=CH- or -CH=N-;
 - A4 and A5 are each CH or N;
 - A6 is CH2, NH, N-alkyl or O;
- 15 $-A^7$ and A^{11} are C or N;
 - -A⁸ and A⁹ are CH, N, NH, N(CH₂)_dR⁷ or S;

1932 OF 18 13 No. Access continued by 190 bit area and the first and assert for a solution of the continued and the cont

- A¹⁰ is -CH=CH-, CH, N, NH, N-(CH₂)_d-R⁷ or S;
- A¹² and A¹³ are N or C and
- A¹⁴, A¹⁵ and A¹⁶ are NH, N-CH₃, S, N or CH,
- provided that not more than one of A⁰, A⁹ and A¹⁰ is NH, N-(CH₂)_d-R⁷ or S;
- that A⁷ and A¹¹ are not both simultaneously N; that neither A⁷ nor A¹¹ is N if one of A⁸, A⁹ and A¹⁰ is NH, N-(CH₂)_d-R⁷ or S;; that if A¹⁰ is not -CH=CH-then one of A⁸, A⁹ and A¹⁰ is NH, N-(CH₂)_d-R⁷ or S or one of A⁷ and A¹¹ is N; that not more than one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S; that A¹² and A¹³ are not both simultaneously N; that if one of A¹⁴, A¹⁵ and A¹⁶ is NH,
- N-CH₃ or S then A¹² and A¹³ are both C; and that one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S or one of A¹² and A¹³ is N;
 - X1 is O or NH;
 - R¹, R² and R³ are each H, alkyl, O-alkyl, F, Cl or Br;
 - -R⁴ is H, alkyl, optionally substituted phenyl, pyridyl, thienyl or furyl, or is
- 15 -(CH₂)_e-R^{g:}
 - R⁵ and R⁶ are each, independently of each other, alkyl, Ar or -(CH₂)_r-Ar, where Ar is optionally substituted phenyl or thienyl;
 - R⁷ and R⁸ are each; independently of each other, H, alkyl, optionally substituted phenyl, pyridyl, thienyl or furyl, F, OH, O-alkyl, S-alkyl, O-acyl, NH₂,
- NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN or CF₃;
 - a is 1 or 2, b is 1, 2 or 3, c is 1 or 2, d is 1, 2 or 3; e is 1, 2 or 3 and f is 1, 2 or 3.

According to a first aspect, the present invention relates to novel OT agonists and/or VP-antagonists, and in particular specific antagonists of the V_{1a} receptor, and pharmaceutically acceptable salts thereof.

According to a second aspect, the present invention relates to pharmaceutical compositions comprising these novel compounds, which compositions are useful for the treatment of, *inter alia*, male erectile dysfunction and primary dysmenorrhoea.

According to a third aspect, the present invention relates to the use of these novel compounds for the manufacture of a pharmaceutical composition for the treatment of erectile dysfunction.

According to a fourth aspect, the present invention relates to the use of the compounds in the above mentioned series of potent and specific OT recep-

20. For 4 C15.28 C. Ar Great senton I FRE RC PHARM SCI UTA & SASSON TO DE FERSING PARTICIPAN AND STORY OF THE PROPERTY OF THE

tor agonists and/or VP receptor antagonists for the manufacture of a pharmaceutical composition for treatment of dysmenorrhoea.

According to further aspects, the present invention relates to the use of the above mentioned compounds and compositions in therapy and to therapeutic methods wherein the above mentioned compounds and compositions are used.

DETAILED DESCRIPTION OF THE INVENTION

Thus, according to the first aspect, the present invention relates to novel specific OT agonists and/or novel specific V_{1a} antagonists. These compounds are benzyl carbamates and areas having the general formula 1:

In this general formula the substituents R^1 , R^2 and R^3 are, independently of each other, selected from hydrogen (H), alkyl groups, alkoxy (O-alkyl) groups, and the halogens fluorine (F), chlorine (Cl) and bromine (Br). Preferably, at least one of R^1 , R^2 and R^3 is H and at least one is not H. More preferably, two of R^1 , R^2 and R^3 are H, and the other is an alkyl group; an O-alkyl group or a halogen.

The linking group X¹ is selected from oxygen (O) and unsubstituted introgen (NH). Preferably, X¹ is NH.

The integer a may be 1 or 2, and the integer b may be 1, 2 or 3. Preferably a is 1 and b is 2 such that this ring is a piperazine.

The substituent R^4 is selected from H, alkyl groups, alkenyl groups, alkynyl groups, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl groups, a group— $(CH_2)_cR^8$, wherein e is 1, 2, 3 or 4, $-CH_2$ -CH= $-CH_2$ -CH $-CH_2$ -R 8 , $-CH_2$ -C= $-CH_2$ -R 8 , $-CH_2$ -C= $-CH_2$ -R 8 , wherein g and h are, independently of each other, 1 or 2, $-(CH_2)_i$ -O- $-(CH_2)_j$ -R 8 wherein i and j are, independently of each other, 1 or 2, and

Posts of the to the very configuration for better of the transfer to the first solution of the property of the property of the solution of the configuration of the configuration

15

CH₂ R⁰

wherein R⁸ is selected from H, F, CF₃, alkyl groups, alkenyl groups, alkynyl groups, acyl groups, O-alkyl groups, S-alkyl groups, O-acyl groups, hydroxyalkyl groups, amino groups such as NH2, NH-alkyl, N(alkyl)2, 1-pyrrolidinyl, 1-piperidinyl and 4-morpholinyl, NH-acyl, N(alkyl)-acyl, CO2H, CO2-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrrolyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl and optionally substituted isothiazolyl groups. Suitable optional substituents for the phenyl, pyridyl, thienyl, furyl, pŷrrolyl, pŷrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl groups in R4 and R8 include F, Cl, Br, CF3, alkyl groups, OH, O-alkyl groups, hydroxyalkyl groups, amino groups such as NH2, NH-alkyl and N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONHalkyl, CON(alkyl)2, oxadiazolyl, thiadiazolyl, CN and NO2. The phenyl, pyridyl, thienyl furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl or isothiazolyl group may have up to three such substituents which may be the same or different.

The group G¹ is a disubstituted nitrogen such that the C(=O)-G¹ bond is an amide bond. G¹ is selected from an acyclic group according to general formula 2, a fused bicyclic group according to general formulae 3, 4 and 5, and a fused tricyclic group according to general formulae 6 and 7.

2003 02 1 (1842 V) holders of model (188120) 2 (2884) OF (1941) Als Asspect (27) and only (1921) of the complete supplied model (1882) (1

In general formula 2, R⁵ and R⁶ are, independently of each other, selected from alkyl, Ar and –(CH₂)_f–Ar, wherein f is 1, 2 or 3 and Ar is selected from optionally substituted thienyl and optionally substituted phenyl. Suitable substituents for the phenyl group are alkyl groups, OH, alkoxy groups, halogens, NH₂, NH–alkyl and N(alkyl)₂. The phenyl group may be substituted with up to three such substituents which may be the same or different.

In general formula 3, A¹ is selected from CH₂, CH(OH), NH, N-alkyl, O and S. A² is selected from CH₂, CH(OH), C(=O) and NH, and c is 1 or 2, preferably 2. It is preferred that when A² is NH then A¹ is CH₂. It is also preferred that when A² is C(=O) then A¹ is NH or N-alkyl.

In general formulae 3, 6 and 7, A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH=N- and A⁴, and A⁵ are each, independently of each other, selected from CH and N. In a preferred embodiment, A³ is S and A⁴ and A⁵ are both CH, so as to form a thiophene ring. In another preferred embodiment, A³ is -CH=CH- and A⁴ and A⁵ are both CH, so as to form a benzene ring. In another preferred embodiment, A³ is -CH=N- and A⁴ and A⁵ are both CH, so as to form a pyridine ring. In another preferred embodiment, A³ is -CH=CH-, A⁴ is CH and A⁵ is N, again so as to form a pyridine ring.

In general formulae 4 and 6, A⁶ is selected from CH₂, NH, N-alkyl and O, A⁷ and A¹¹ are, independently of each other, selected from C and N, A⁸ and A⁹ are, independently of each other, selected from CH, N, NH, N-(CH₂)_d-R⁷ and S, and A¹⁰ is selected from -CH-CH-, CH, N, NH, N-(CH₂)_d-R⁷ and S, wherein d is 1, 2 or 3 and R⁷ is selected from H, F, CF₃, alkyl groups, OH, O-alkyl groups, S-alkyl groups, O-acyl groups, amino groups such as NH₂, NH-alkyl and N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and optionally substituted phenyl groups. Suitable optional substituents for the phenyl groups in R⁷ include F, Cl, Br, CF₃, alkyl groups, O-alkyl groups, amino groups such as NH₂, NH-alkyl and N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂-alkyl, CONH₂, CONH-alkyl,

2013 92 14 15343 93 Red remain anach discrete principles of the Lie of Standard Control Nothern Red and Sp. Front St. Library

CON(alkyl)₂, CN and NO₂. The phenyl group may have up to three such substituents which may be the same or different.

The ring constituted by A⁷, A⁸, A⁹, A¹⁰ and A¹¹ is aromatic, and accordingly the groups must satisfy certain requirements. When A¹⁰ is -CH=CH- the ring is a six-meinbered ring. As such, it can only comprise atoms of the type -C(R)= and -N=. Hence A⁷ and A¹¹ must both be C and A⁸ and A⁹ must be either CH or N. When A¹⁰ is not -CH=CH- then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a "trigonal nitrogen" is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when A¹⁰ is not -CH=CH- then one (and only one) of A⁷, A⁸, A⁹, A¹⁰ and A¹¹ must be S or a trigonal nitrogen. Hence the selection of A⁷, A⁸, A⁹, A¹⁰ and A¹¹ is subject to the following restrictions:

- 1) If A¹⁰ is not -CH=CH-, then one of A⁸, A⁹ and A¹⁰ is NH, N-(CH₂)_d-R⁷ or S or one of A⁷ and A¹¹ is N.
- 2) Not more than one of A⁸, A⁹ and A¹⁰ may be NH, N-(CH₂)_d-R⁷ or S.
- 3) A^7 and A^{11} may not both simultaneously be N.
- 20 4) Neither A⁷ nor A¹¹ may be N if one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S

In a preferred embodiment, A^6 is NH. In another preferred embodiment, A^6 is NH or $N-(CH_2)_d-R^7$. In an even more preferred embodiment, A^6 is NH or $N-(CH_2)_d-R^7$, and A^9 is N and A^{10} is CH.

In general formulae 5 and 7, A¹² and A¹³ are selected from N and C and A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH. Again, these atoms constitute an aromatic five-membered ring and so there must be one, and only one, S or trigonal nitrogen. Hence the selection of A¹², A¹³, A¹⁴, A¹⁵ and A¹⁶ is subject to the following restrictions.

- 30 1) One of A^{14} , A^{15} and A^{16} is NH, N-CH₃ or S or one of A^{12} and A^{13} is N.
 - 2) Not more than one of \overline{A}^{14} , A^{15} and A^{16} is NH, N-CH₃ or S.
 - 3) A¹² and A¹³ may not both simultaneously be N.
 - 4) If one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S then A¹² and A¹³ are both C As used herein, the term "alkyl" or "alkyl group" is intended to designate lower alkyl groups, i.e. saturated hydrocarbon groups of between one and six

lower alkyl groups, i.e. saturated hydrocarbon groups of between one and six carbon atoms, including linear, branched and cyclic alkyl groups. Examples of

"alkyl" include, but are not limited to: C_1 - methyl, C_2 - ethyl, C_3 - propyl, isopropyl, cyclopropyl, C_4 - n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, cyclopropylmethyl, methylcyclopropyl, C_5 - n-pentyl, neopentyl, cyclopropylethyl, dimethylcyclopropyl, and C_6 - n-hexyl, cyclohexyl, bicyclo[3.1.0]hexyl.

The term "alkenyl" or "alkenyl group" denotes a lower alkenyl group, i.e. a mono-unsaturated hydrocarbon group of between two and six carbon atoms, including linear, branched and cyclic alkenyl groups. Examples of "alkenyl" include, but are not limited to: C_2 - vinyl, C_3 - allyl, 1-methylvinyl, 1-propenyl, C_4 but-3-enyl, but-2-enyl, methallyl.

The term "alkynyl" or "alkynyl group" denotes a lower alkynyl group, i.e. an unsaturated hydrocarbon group of between two and six carbon atoms which includes a carbon-carbon triple bond, including linear, branched and cyclic alkynyl groups. Examples of "alkynyl" include, but are not limited to: C₂ - ethynyl, C₃ - propargyl, 1-propynyl.

The term "hydroxyalkyl" denotes an alkyl group as defined above in which one or more of the hydrogen atoms are replaced by hydroxyl groups (OH). In general, not more than one hydroxyl group will be attached to any particular carbon atom within the hydroxalkyl group. Examples of hydroxyalkyl groups include, but are not limited to: hydroxymethyl (HOCH₂), 1-hydroxyethyl (CH₃CH(OH)), 2-hydroxyethyl (HOCH₂CH₂); 1,2-dihydroxyethyl (HOCH₂CH(OH)) 4-hydroxy-2-pentyl (CH₃CH(OH)CH₂CH(CH₃)), and 4-hydroxycyclohexyl.

The term "acyl" denotes a group R-C(=0), where R is H, a saturated or unsaturated hydrocarbon moiety of up to seven carbon atoms or a pyridyl or thienyl group. Examples of acyl groups include, but are not limited to: formyl, acetyl, pivaloyl, benzoyl and nicotinoyl.

The compounds according to the present invention generally contain a basic nitrogen atom and so are capable of forming addition salts with protic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, benzoic acid, maleic acid, citric acid, fumaric acid, methanesulphonic acid and the like. The compounds of the present invention may also contain an acidic group, such as a carboxylic acid group at R7 or R8 These compounds may exist as inner salts (zwitterions) or as salts such as sodium, potassium, magnesium, calcium or tetra-alkylammonium salts. To the

extent that such salts are pharmaceutically acceptable, they are included within the scope of the present invention.

The compounds according to the present invention may have one or more stereogenic centres ("asymmetric carbon atoms") and so may exhibit optical isomerism. The scope of the present invention includes all epimers, enantiomers and diastereomers of compounds according to general formula 1, including single isomers, mixtures and racemates.

Particularly preferred embodiments within the present invention are those compounds that combine two or more of the preferred features described above.

One such particularly preferred embodiment is a urea according to general formula 8.

In general formula 8, R¹, R², R³, R⁴ and G¹ are as previously defined.

Another particularly preferred embodiment is a compound according to general formula 9, which corresponds to a compound according to general formula 1 in which G¹ is a group according to general formula 6 wherein A⁴, A⁵ and A¹⁰ are all CH, A⁶ is NH, A⁷ and A¹¹ are both C, A⁸ is N(CH₂)_dR⁷ and A⁹ is N.

200 05 115.15 V. Reforming on Thorago property with the Artistic of the National Politicity of the Artistic of the Reforming The Artistic of t

In general formula 9, R¹, R², R³, R⁴, R⁷, A³, X¹, a, b and d are as previously defined.

A most preferred embodiment is a compound according to general formula 10.

In general formula 10, R^1 , R^2 , R^3 , R^4 , R^7 , A^3 and d are as previously defined.

Individual preferred compounds within the invention include:

4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3 methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azuleñe-9-carbonyl)-benzylamide;

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3 fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine 1-carboxylic acid-20 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9carbonyl)-benzylamide;

4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

	1.5
•	4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-
	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-
	penzylamide; }
٠٠.	4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-
5	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-
	benzylamide;
	4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-
	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-
	benzylamide;
10	4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-piperazine-1-carboxylic aci
	4,10-diliydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl]-benzylamide;
	4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-
•	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-
	benzylamide;
15	4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-
	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-
:	benzylamide;
•	4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-
	dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
20.	4-Hexyl-ninerszine-1-nathowskie-acid 0
•	4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2) 4 9-tetraggy-bargotelessels 2
•	dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
	(R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4-10-dihydro-34-2-3-4-0 acid 2-methyl-4-10-dihydro-34-2-3-4-0 acid 2-methyl-4-10-4-10-4-0 acid 2-methyl-4-10-4-10-4-10-4-10-4-10-4-10-4-10-4-1
	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)- benzylamide;
25	
	4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4-10-dihydro-3H-2 3 4 9 toppose 1 5 3
٠.	4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
•	4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-
	methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)- benzylamide;
30	
	4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-
•	methyl-4;10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)- benzylamide;
••	oortsylaimide,
	4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-
5	y v carry did-yri-2,5,4,9-lettaaza-benzolf (azulena () an-barrati la did-
	VJ VIOULYLLIGHTYL-DIDEFAZING-1-Carbovyllic cold O. Gisser d. Co.
•	4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
•	William consists and the manifest of the control of

.: 15

30

Empfansszeit 14. Feb. 16:14

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and

4-Cyclobutylinethyl-piperazine-1-carboxylic acid 3-inethoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-

5 benzylamide.

Other individual preferred compounds, especially for treatment of primary dysmenorrhoea, and also for treatment of pre-term labour, Raynauld's disease,, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hypomatremia, liver cirrhosis or congestive heart failure, within the invention include:

4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2†methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and

4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4 25 (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)benzylamide.

These individually preferred compounds have several advantages over existing entities. They are selective for the V_{1a} receptor over other AVP receptors. Thus they are potentially safer and more effective than existing non-selective entities. Existing V_{1a} selective entities have been suspended during development due to issues such as safety. Furthermore, they are non-peptidic small molecules. It is well known that such compounds have significantly more potential to be orally active than peptides. As such they offer more convenience and better patient compliance than peptidic entities.

The compounds of the present invention can be prepared by standard chemical manipulations. In general, compounds according to general formula 1 can be considered to consist of three component parts:

Component C¹ corresponding to G¹

• Component C² corresponding to the substituted benzoyl unit

• Component C3 corresponding to the saturated heterocycle

Intermediates corresponding to these components are prepared and then assembled to give the final product. These three components are:

(i), for C¹, a secondary amine

G¹-H

(ii) for C2, a substituted benzoic acid

 R^2 X^1 H

(iii) for C³, a monosubstituted saturated heterocycle

 $\int_{-(CH_2)_a}^{-(CH_2)_a}$ $HN = \int_{(CH_2)_b}^{+}$

It will be recognised that the substituted benzoic acid that serves for C² has two functional groups, one of which will need temporary protection during the assembly of the final compound. The principles of functional group protection are well known in the art and are described in, for example, J.F.W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, 1973; T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd edition, John Wiley, 1991; and P.J. Kocienski, "Protecting groups", Georg Thienie Verlag, 1994. The carboxylic acid group will usually be protected as

2003-02-14-15046 V. Bushraardee logist. Black This amachet Tickle and Stratllet. Robustally (The 2000-80) innings.

an ester, such as the methyl, benzyl or tert-butyl ester. The primary amine of the benzoic acid (when $X^l = NH$) will usually be protected as a carbamate derivative such as the *tert*-butyl carbamate (BOC derivative), the benzyl carbamate (CBZ or more simply Z derivative) or the 9-fluorenylmethyl carbamate (Fmoc derivative). When $X^l = 0$ the resulting alcohol function will usually be protected as an ester such as an acetate, or an ether such as a methoxymethyl, tetrahydropyranyl or trialkylsilyl ether. Other functional groups may require protection. For example, the group G^l may include one or more primary or secondary amino groups which may need protection. In the following general description of the synthetic methodology it will be assumed that such protection is used when necessary.

(i) Preparation of secondary amine for C'

Acyclic secondary amines corresponding to HNR⁵R⁵ are well known. Many are items of commerce. Those that are not may be prepared according to published methods or by simple modification of such methods. Some particularly useful methods are listed below.

a) Alkylation

20

(This method is only applicable in cases where further alkylation can be avoided.)

b) Reductive animation

$$R^{5}$$
 NH_{2} $+$ O R^{5} R^{5} R^{5} R^{6}

(where RaCHRb corresponds to Rb)

c) Amide reduction

(where RaCH2 corresponds to R6)

The starting amide can itself be prepared using well known methods.

$$R^{5}$$
 NH_{2} R^{5} NH_{2} R^{5} NH_{2} R^{5} R^{5} NH_{2} R^{5} NH_{2}

Secondary amines corresponding to C¹ where G¹¹ is a group according to general formulae 3 = 7 are generally not commercially available. They can be prepared according to published methods, or by obvious modifications of such methods. Particularly useful methods are described in: Aranapakam et al., Bioorg. Med. Chem. Lett. 1993, 1733; Artico et al., Farmaco. Ed. Sci. 24, 1969, 276; Artico et al., Farmaco. Ed. Sci. 32, 1977, 339; Chakrabarti et al., J. Med. Chem. 23, 1980, 878; Chakrabarti et al., J. Med. Chem. 23, 1980, 884; Chakrabarti et al., J. Med. Chem. 32, 1989, 2573; Chimirri et al., Heterocycles 36, 1993, 601; Grunewald et al., J. Med. Chem. 39, 1996, 3539, Klunder et al., J. Med. Chem. 35, 1992, 1887; Liegéois et al., J. Med. Chem. 37, 1994, 519; Olagbemiro et al., J. Het. Chem. 19, 1982, 1501; Wright et al., J. Med. Chem. 23, 1980, 462, Yamamoto et al., Tet. Lett. 24, 1983, 4711; and International patent application, publication number WO99/06403.

(ii) Preparation of substituted benzoic acid for C2

Substituted benzoic acids corresponding to C² are not generally items of commerce, but they can be prepared using published methods or obvious variations of such methods. The main challenge is generally the elaboration of the CH₂X¹H functionality at the 4-position. Some useful transformations are listed below.

Source 1915 as V. Address regard 1990s, Pharmacologic & S. v. P.A. 1945. Notablication and propertients a supplication of the contraction of the c

a) Bromination/Substitution

b) Sandmeyer

10

(iii) Preparation of heterocycle derivative for C3

Certain heterocycles corresponding to C³, particularly N-aryl piperazines, are items of commerce. Other heterocycles can be prepared according to the methods described in the literature. Useful transformations include the following

a) Alkylation or reductive alkylation

(where PG is a protecting group and RACH2 is R4)

| 001 | 02 | 4 | 15:40 | 5 | 000 | gamelling 14 | 000 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001 | 001

b) Acylation/reduction

c) Reduction

With the three components, suitably protected if necessary, in hand, the assembly of the final compound requires the formation of two bonds: between C^1 and C^2 , and between C^2 and C^3 . These bond-forming steps may be taken in either order. Thus, the following sequences can be proposed:

$$C^{1} + C^{2} \rightarrow C^{1}C^{2} \rightarrow C^{1}C^{2}C^{3}$$

$$C^{2} + C^{3} \rightarrow C^{2}C^{3} \rightarrow C^{1}C^{2}C^{3}$$

(i) Formation of C'-C2 bond

20

25

The bond between C and C is a simple amide bond. The chemistry for making such bonds from a carboxylic acid and a secondary amine is well known in the art of organic synthesis, and particularly in the field of peptide synthesis. The carboxylic acid may be converted into a more reactive species such as an acid chloride (using, for example oxalyl chloride or thionyl chloride) or a mixed anhydride (using isobutyl chloroformate). This reactive species is then added to the secondary amine in a suitable solvent, generally an aprotic solvent such as dichloromethane or dimethylaminopyridine, and the reaction is allowed to proceed at a temperature between -20°C and the boiling point of the solvent. The choice of temperature and the time allowed for the reaction will depend on the reactivity of the two components.

Alternatively, the carboxylic acid and the secondary amine may be mixed in a suitable solvent as above, optionally in the presence of a base, and a condensing agent added. Suitable condensing agents include carbodiimides, such as dicyclohexylcarbodiimide (DCC) and N-ethyl-N'-

dimethylaminopropylcarbodiimide (EDC, also WSCD for water-soluble carbodiimide), phosphorus reagents such as (benzotriazol-1-yloxy)-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP®) and bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP®), and ureas such as O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU).

(ii) Formation of C2-C3 bond

10

The bond between C^2 and C^3 is a carbamate (when $X^1 = O$) or a urea (when $X^1 = NH$). The first step in the formation of this bond is generally to react the heterocycle derivative with phosgene or a phosgene equivalent such as trichloromethyl chloroformate, bis(trichloromethyl)carbonate or carbonyl-diimidazole. Again, an aprotic solvent and a tertiary amine base will generally be used. The infermediate formed in this step is usually not isolated. The alcohol ($X^1 = O$) or amine ($X^1 = NH$) is added and the reaction is allowed to continue, directly forming the carbamate or urea. As an alternative, when $X^1 = NH$ the reactive intermediate may be formed by the reaction of C^2 with the phosgene equivalent and the amine added in the second part of the synthesis.

The compounds according to the present invention are useful in human and animal therapy.

As stated above, the second, third and fourth aspect of the present invention relates to pharmaceutical compositions comprising the above described compounds and to the manufacture of pharmaceutical compositions using the above described compounds. In such pharmaceutical compositions, the above described compounds constitutes a pharmaceutically active ingredient. It may be the sole active ingredient, or it may be combined by at least one other active ingredient or agent. Preferably the pharmaceutical composition includes no additional active agents. Normally, the pharmaceutical compositions according to the invention, used according to the invention or produced according to the invention also comprise other substances, such as an inert vehicle, or pharmaceutical acceptable adjuvants, carriers, preservatives etc., which are well known to persons skilled in the art.

The pharmaccutical composition according to the present invention may be presented in any form that is known in the art. For example, the formulation may be presented as a tablet, capsule, powder, suppository, cream, solution or

2016-02-14 Forda V *Moritaging aging legislagat, programment of the ALNASOACT of the Reference of the Programment was Complete Control of the Complete Control of the Complete Control of the Complete Control of the Co

suspension, or in a-more complex form such as an adhesive patch. The formulation will generally include one or more excipients, such as diluents; bulking agents, binding-agents, dispersants, solvents, prescrivatives, flavouring agents and the like. Where the formulation is presented as a tablet or capsule the excipients may optionally include one or more agents to control the release of the active species, such as a coating of a polymer that is insoluble at low pH but soluble at neutral or high pH. Such a coating (known as an "enteric coating") prevents the release of the active agent in the stomach but allows its release in the intestines.

The compounds according to the present invention are useful for treatment of several diseases, disorders or conditions. The term "treatment" used herein relates to both treatment in order to cure or alleviate a disease, disorder or a condition, and to treatment in order to prevent the development of a disease, disorder or a condition. The treatment may either be performed in an acute or in a chronic way. The human or animal to be treated, i.e. the patient, may be any human or non-human mammal in need of treatment according to the invention.

The novel compounds of the present invention are potent and selective OT agonists and/or V_{1a} receptor antagonists and so they and pharmaceutical compositions comprising them are useful in the treatment of treatment of conditions for which inadequate oxytocin-like activity is implicated in the pathophysiology and in the treatment of conditions in which inappropriate vasopressin-like activity is implicated in the pathophysiology. Conditions for which inadequate oxytocin-like activity is implicated in the pathophysiology include, but are not limited to: sexual disorders such as male erectile dysfunction, ejaculatory disorders and female sexual dysfunction, cancer of the prostate, breast, ovary and bones, osteoporosis, benign prostatic hyperplasia, postpartum bleeding, and depression. Conditions in which inappropriate vasopressin-like activity is implicated in the pathophysiology include disorders atfeeting blood plateleis, blood vessels, hepatocytes, brain aud uterus-cervix. The novel V1a receptor antagonist and/or pharmaceutical compositions comprising them are suitable for treatment of primary dysmenorthoea, pre-term labour, hypertension, Raynauld's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure. In a preferred embodiment, the compounds or pharmaceutical

250.5-02-14 broad & [NCOrganical cel BERTME JUARWOOD BURGARING JUARWOOD BY A LANGUAGE ASSESSMENT FOR TWO PROPERTY FOR THE APPROPRIATE FOR THE PROPERTY FOR THE

10

15

compositions according to the invention are used for treatment of primary dysmenorrhoea.

Further aspects of the invention relates to methods for treatment of the

above mentioned diseases, disorders or conditions, and preferably a method for treatment of primary dysmenorrhoea. According to the method according to the invention a therapeutically effective amount of the compound, or of the pharmaceutical composition, described above is administered to a patient in need of this treatment.

The term "therapeutically effective amount" relates to an amount that will lead to the desired therapeutical effect. The therapeutically effective amount will be determined by the attending physician taking into considerationall appropriate factors. Generally a single dose will comprise between 0.1 mg and 1000 mg, preferably between 1 mg and 250 mg, of the active compound according to the invention. The dose may be given on a single occasion or repeatedly. When given repeatedly, it may be given at regular intervals, such as once, twice or three times daily, or on demand, according to the condition being treated.

When used as the apeutic agents, the compositions of the present invention may be administered by any appropriate route that is known in the art. For example, they may be administered by the oral, buccal, sublingual, rectal, intravaginal, nasal, pulmonary or transdermal routes. Alternatively, they may be given by injection, including intravenous, subcutaneous and intramuscular injection.

For long-term treatment an alternative to repeated dosing may be the administration of a depot dose. For this method of administration the active agent is generally introduced into a matrix of biodegradable polymer, such as a copolymer of lactic and glycolic acids, and the formulation is given either subcutaneous (s.c.) or intramuscularly (i.m.) so as to form a deposit from which the active agent is released as the polymer degrades.

In order to decide whether or not a compound having general formula I is a selective V_{1a} antagonist the compound may be assayed to determine its ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, the compounds cause significant inhibition of cellular activation at concentrations of 30µM or less. Preferred compounds cause significant inhibition at concentrations of 300 nM or less.

2002-02 14 15 16 V. Photogrameaton Chirality Plans At Letter via assisting strong him benefition surrounding. Application on Mark 2002-01-31 1 dec

20

25

30

·35

The present invention is further illustrated in the following examples, which are intended to demonstrate the application of the invention but not to limit the scope thereof.

5 EXAMPLES

The following abbreviations are used:

Bu butyl - alkyl residues may be further denoted as n (normal, i.e. un-

branched), i (iso) and t (tertiary)

DIEA N,N-diisopropylethylamine

DMF dimethylformamide

Et ethyl

EtOAc ethyl acetate

HOBt 1-hydroxybenzotriazole

HPLC high pressure liquid chromatography

h hour(s)
Me methyl

MS mass spectrum

NMR nuclear magnetic resonance spectrum - NMR spectra were recorded

in CDCl3 unless etherwise indicated

OVA or withing vasotocin analogue

pet. petroleum ether boiling in the range 60-80°C.

ether

Ph phenyl

Pn pentyl

Pr propyl

THF tetrahydrofuran.

WSCD water-soluble carbodiimide (N-ethyl-N'-(3-dimethylaminopropyl)-

carbodiimide hydrochloride.

Examples 1 – 13 describe the synthesis of intermediates. Compounds according to the present invention are described in Examples 14 – 149. Example 150 describes how compounds can be assayed based on their ability to inhibit the cellular consequences of AVP stimulation on intact cells. Example 151 describes tablets for oral administration comprising a compound according to the invention.

Soft 02-13 18 on V. Advisor Software Property of Control of Test And Assistant Northware Indicated and including the Control of the Control of Control of

Example 1

1-Benzyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

1A: Ethyl 5-amino-1-benzylpyrazole-4-carboxylate

Benzylhydrazine dihydrochloride (4.29 g, 22 mmol) was added to a solution of ethyl (ethoxymethylene) cyanoacetate (3.38 g, 20 mmol) and triethylamine (6.15 ml, 44 mmol, 2 eq) in ethanol (40 ml) and the mixture was heated at reflux for 18h. The solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (eluant 60% pet. ether/40% ethyl

THE OR THE SPACE YOUR MERCANDISH REPORTED FRANCE OF THE ALL LAST PACTURE MERCANDISM CARREST MERCANDISM CARRE

acetate) to yield a pale yellow solid identified as ethyl 5-amino-1-benzyl-pyrazole-4-carboxylate (4.3 g, 88%).

1B: Ethyl 1-benzyl-5-(2'-uitrophenylamino)pyrazole-4-carboxylate

Sodium hydride (60% dispersion in oil, 520 mg, 13 mmol) was added portionwise to a suspension of ethyl 5-amino-1-benzylpyrazole-4-carboxylate (2.2 g, 9 mmol) in anhydrous THF (30ml) at 0°C. The mixture was allowed to warm to room temperature and stirred for 2h then 1-fluoro-2-nitrobenzene (1.26 g, 9 mmol) was added and the resultant deep purple suspension was stirred at room temperature for 18 h. 1 M KHSO₄ was added to quench the reaction and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate and the solution was washed with 0.3 M KHSO₄, sat. NaHCO₃ and brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 75% pet. ether/25% ethyl acetate) to yield ethyl 1-benzyl-5-(2'-nitrophenylamino)pyrazole-4-carboxylate (2.5 g, 76%).

 $MS [M+H]^{+} 366.8$

10

25

20 1C: Ethyl 5-(2'-aminophenylamino)-1-benzylpyrazole-4-carboxylate

Ethyl 1-benzyl-5-(2'-nitrophenylamino)pyrazole-4-carboxylate (2.5 g, 6.8 mmol) was dissolved in ethyl acetate/ethanol (1:1, 100 ml) and hydrogenated over 10% Pd/C catalyst for 70 minutes. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a white solid identified as ethyl 5₇(2'-aminophenylamino)-1-benzylpyrazole-4-carboxylate (1.5 g, 86%).:

MS [M+H]+337.2

1D: 1-Benzyl 4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepin-4(5H)-one

A solution of ethyl 5-(2'-aminophenylamino)-1-benzylpyrazole-4-carboxylate (1.75 g, 5.2 mmol) in acetic acid/2-propanol (1.9, 40 ml) was heated at reflux for 3 days. The solvent was removed in vacuo and the residue was azeotroped with toluene to give an off-white solid that was purified by flash chromatography on silica gel (eluant 35% pet. ether/65% ethyl acetate) to

20-13-12 1-1 (the see has regarded in Figure 19), but are the restriction of the second of the secon

yield a white solid identified as 1-benzyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepin-4(5H)-one (780 mg, 52%).

MS [M+H]⁺291.1

1E: 1-Benzyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

LiAlH, (365 mg, 10 mmol) was added portionwise to a suspension of 1-benzyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepin-4(5H)-one (780 mg, 2.7 mmol) in anhydrous THF (15 ml) at 0°C over 10 min. The resulting suspension was heated at reflux for 18 h, then allowed to cool to room temperature. A further portion of LiAlH, (90 mg, 2.5 mmol) was added and the mixture was heated at refluxed for 3 h. The mixture was cooled to 0°C, 35% ammonia solution (1 ml) was added dropwise over 10 min and the mixture was stirred at room temperature for 1h. The resulting suspension was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a white solid identified as 1-benzyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (450 mg, 60%).

MS [M+H]+ 276.9

20

10

Example 2

1-Methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazopine

2A: Ethyl 1-methyl-2-(3'-nitro-2'-pyridylamino)pyrazole-4-carboxylate

Sodium hydride (60% dispersion in oil, 600 mg, 15mmol) was added portionwise to a suspension of ethyl 5-amino-1-methylpyrazole-4-carboxylate (1.69 g, 10 mmol) in anhydrous THF (15ml) at 0°C. The mixture was stirred for 2h at room temperature then 2-chloro-3-nitropyridine (1.58 g, 10 mmol) was added and the resulting deep red suspension was stirred at room temperature for 18 h. I M KHSO₄ was added to quench the reaction and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate and the solution was washed with 0.3 M KHSO₄, sat. NaHCO₃ and brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 30% pet. ether/70% ethyl acetate) to give ethyl 1-methyl-2-(3'-nitro-2' pyridylamino)pyrazole-4-carboxylate (1.95 g, 67%).

MS'[M+H]+292.0

December 1948 V. Mediczerianian dell'Activistic partic de est effett, paramie trezimiese appois a Legi ciatimiese Marc (1973-1965), è pos 2B: Ethyl 2-(3'=amino-2'-pyridylamino)-1-methylpyrazole-4-carboxylate

A solution of ethyl 1-methyl-2-(3'-nitro-2'-pyridylamino)pyrazole-4-carboxylate (1.95 g, 6.7 minol) in ethanol (100ml) was hydrogenated over 10% Pd/C catalyst for 3 l. The reaction mixture was filtered through Celite[®] filter agent and the filtrate was concentrated in vacuo to give a white solid identified as ethyl 2-(3'-amino-2'-pyridylamino)-1-methylpyrazole-4-carboxylate (1.5 g, 86%).

10 2C: 1-Methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepiu-4(5H)-one

A solution of ethyl 2-(3'-amino-2'-pyridylamino)-1-methylpyrazole-4-carboxylate (1.5 g, 5.75 mmol) in acetic acid/2-propanol (1:9, 50 ml) was heated at reflux for 3 days. The solvent was removed in vacuo and the residue was azeotroped with toluene. The residue was purified by recrystallization from ethanol and then flash chromatography on silica gel (cluant 95% chloro-form/4% methanol/1% acetic acid) to give a white solid identified as 1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepin-4(5H)-one (560 mg, 45%).

2D: 1-Methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine

LiAlH4 (365 mg, 10 mmol) was added portionwise to a suspension of 1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepin-4(5H)-one (560 mg, 2.6 mmol) in anhydrous THF (30 ml) at 0°C over 10 minutes. The resulting suspension was heated at reflux for 18 h. The reaction was cooled to 0°C and 35% ammonia solution (1 ml) was added dropwise over 10 minutes, then the mixture was stirred at room temperature for 1 h. The resulting suspension was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a white solid identified as 1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine (410 mg, 78%).

MS [M+H] + 202.1.

30

5

JOFF 62-14 Endex of Notingariamental DINCOPHARM OF COMPARA SASSING TO COLOR SECURITION OF A MODIFIED ASSESSMENT OF THE COLOR OF THE COLOR OF A MODIFIED ASSESSMENT OF THE COLOR OF THE

Example 3

tert-Butyl 4-aminomethyl-3-chlorobenzoate

3A: tert-Butyl 3-chloro-4-methylbenzoate

Thionyl chloride (11 ml, 150 mmol) was added to a suspension of 3-chloro-4-methylbenzoic acid (5.12 g, 30 mmol) in toluene (25 ml) and the mixture was heated at reflux for 2 h. The solvent was removed in vacuo and the residue was azeotroped with toluene three times, then dissolved in anhydrous THF (40 ml) and cooled to 0°C. Lithium tert-butoxide (2.4 g, 30 mmol) was added and the mixture was stirred at room temperature for 3 days. Water (5 ml) was added and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate. The solution was washed with 0.3M KHSO₄, sat. NaHCO₃ and brine, dried over Na₂SO₄ and concentrated in vacuo to give a pale yellow gurn identified as 7ert-butyl 3-chloro-4-methylbenzoate (5.4 g, 79%).

3B: tert-Butyl 4-bromomethyl-3-chlorobenzoate

N-Bromosuccinimide (4.27 g, 24 mmol) and 2,2'-azo-bis(2-methylpropionitrile) (394 mg, 2.4 mmol) were added to a solution of tert-butyl 3-chloro-4-methylbenzoate (5.4 g, 23.8 mmol) in carbon tetrachloride (75 ml) and the mixture was heated at reflux for 18 h. The solvent was removed in vacuo and the residue was purified by flash chromatography on silica gel (cluant 95% pet.cther/5% ethyl acetate) to give a white solid identified as tert-butyl 4-bromomethyl-3-chlorobenzoate (5.7 g, 78%).

3C: tert-Butyl 4-aminomethyl-3-chlorobenzoate

Ethanol (100 ml) was saturated with ammonia, then tert-butyl 4-bromomethyl-3-chilorobenzoate (5.7 g, 18.7 mmol) was added and the mixture was stirred at room temperature for 2 h. The solvent was removed in vacuo and

2013 Oz. (4.15.45.3). Med results of the PRESS PRESS PRESS OF STREET ASSAULT SEE SOMETHING LECTROCOMPAGNICATION OF STREET

the residue was triturated with diethyl ether to give a white solid identified as tert-butyl 4-aminomethyl-3-chlorobenzoate (4.1 g, 91%).

Example 4

4-(tert-Butyloxycarbonylaminomethyl)-3-chlorobenzoic acid

AWAPATENT AB

4A. Methyl 4-bromomethyl-3-chlorobenzoate

To a solution of methyl 3-chloro-4-methylbenzoate (5.0 g, 27.1 mmol) in carbon tetrachloride (50 ml) were added N-bromosuccinimide (5.8 g, 32.0 mmol) and 2,2'-azo-bis(2 methylpropionitrile) (0.442 g, 2.70 mmol). The mixture was heated at reflux for 18 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica (eluant pet. ether \rightarrow 5% ethyl acetate/95% pet. ether) to give an oil identified as methyl 4-bromomethyl-3-chlorobenzoate (5.96 g, 84%).

4B. 4-(tert-Butyloxycarbonylaminomethyl)-3-chlorobenzoic acid To a saturated solution of ammonia in ethanol (170 ml) was added methyl 4bromomethyl 3-chlorobenzoate from Example 4A (5.5 g, 20.9 mmol). The mixture was stirred at room temperature for 1 h and then concentrated in vacuo. The residue was triturated with diethyl ether and the resultant white crystals were filtered off and washed with more diethyl ether. To a solution of this solid in water (100 ml)-were added solutions of di-tert-butyl dicarbonate (5.0 g, 23.0 mmol) in dioxan (100 ml) and sodium hydroxide (1.86 g, 46.0 mmol) in water (100 ml). The mixture was stirred at room temperature for 18h and then concentrated in vacuo. The aqueous residue was acidified with citric acid and extracted with chloroform/2-propanol. The organic layer was washed with water, dried over MgSO4, and concentrated in vacuo to give a white solid identified as 4-(tert-butyloxycarbonylaminomethyl)-3-chlorobenzoic acid (2.8 g, 67%).

25

2003-02-14 15-88 V - [QCO) can o no nobodo ROS (CHARLO) (COLO A (A 58 b X 1594), Flat cano (1823) 8098 03 (co por o A colonio de (1818) [2005-05] (Charlo) (Charlo)

Example 5

4-(tert-Butyloxycarbonylaminomethyl)-3-nitrobenzoic acid

4-Bronomethyl-3-nitrobenzoic acid (4.75 g, 18.2 mmol) was reacted following the method of Example 4B to give a yellow solid identified as 4- (tert-butyloxycarbonylaminomethyl)-3-nitrobenzoic acid (2.6 g, 49%).

Example 6

4-Cyano-3-methylbenzoic acid

To a solution of 4-bromo-2-methylbenzonitrile (2.0 g, 10.2 mmol) in THF (100 ml) at -78°C under a nitrogen atmosphere was added dropwise a 2.5 M solution of n-butyl lithium (4.48 ml, 11.2 mmol). The mixture was stirred at -78°C for 1h and then poured onto solid carbon dioxide (5 g) in THF (50 ml).

The mixture was allowed to warm to room temperature. Water was added (200 ml) and the mixture was extracted with diethyl ether (3 times). The aqueous layer was acidified by addition of concentrated HCl and extracted with chloroform (3 times). The combined chloroform extracts were washed with water, dried over MgSO₄, and concentrated in vacuo to give a white solid identified as

20 4-cyano-3-methylbenzoic acid (1.2 g, 73%).

Applications of the 655-61 of the application of the first of the first of the first of the following the followin

Example 7

4-Cyano-2-methylbenzoic acid

4-Bromo-3-methy benzonitrile (2.0 g, 10.2 mmol) was reacted following the method of Example 6. The product was triturated with hexane to give a yellow solid identified as 4-cyano-2-methylbenzoic acid (0.96 g, 59%).

Example 8

10

4-(tert-Butyloxycarbonylaminomethyl)-2-fluorobenzoic acid

8A. 2-Fluoro 4-methylbenzoic acid :

4-Bromo-3-fluorotoluene (8.33 g, 44.07 inmol) was reacted following the method of Example 6 to give a white solid identified as 2-fluoro-4-methylbenzoic acid (4.89 g, 72%).

that the first is an experience of the first content of the first interest of the first of the f

8B. Methyl 2-fluoro-4-methylbenzoate

To a solution of 2-fluoro-4-methylbenzoic acid (6.04 g, 39.18 mmol) in toluene (80 ml) was added thionyl chloride (65 ml, 89.11 mmol). The mixture was heated at reflux for 2.5 h, cooled and concentrated in vacuo. The residue was dissolved in dichloromethane (50ml) and methanol (50 ml) was added. The mixture was stirred at room temperature for 2.5 h and then concentrated in vacuo. The residue was dissolved in dichloromethane (100 ml), washed with saturated sodium bicarbonate solution and brine, dried over MgSO₄, and concentrated in vacuo to give a tan solid identified as methyl 2-fluoro-4-methylbenzoate (5.07 g, 77%).

8C. Methyl 4-bromomethyl-2-fluorebenzoate

Methyl 2-fluoro-4-methylbenzoate (5.07 g, 30.16 mmol) was reacted following the method of Example of 4A. The product was purified by flash chromatography on silical (eluant 20% ethyl acetate/ 80% pet. ether) to give an oil identified as methyl 4-bromomethyl-2-fluorobenzoate (5.9 g, 80%).

8D. 4-(tert-Butyloxycarbouylaminomethyl)-2-fluorobenzoic acid

Methyl 4-bromomethyl-2-fluorobenzoate (5.9 g, 24.13mmol) was reacted following the method of Example 4B. The product was recrystallised from dioxan/pet. ether to give white crystals identified as 4-(tert-butyloxycarbonylaminomethyl)-2-fluorobenzoic acid (2.4 6g, 38%).

Example 9

30

4-Cyano-3,5-dimethylbeuzoic acid

9A. 4-Bromo 2,6-dimethylbenzonitrile

4-Bromo-2,6-dimethylaniline (4.49 g, 22.4 nunol) was taken up in water (25 ml) and concentrated hydrochloric acid (8.0 ml) was added. The mixture was sonicated to form a fine suspension and then cooled to 0°C. A solution of sodium nitrite (1.67 g, 24.2 mmol) in water (5 ml) was then added dropwise so

STREET STATES AND ADDRESS OF THE STREET STATES AND ADDRESS OF THE STREET STREET ADDRESS OF THE STREET STREET ADDRESS OF THE STREET A

as to maintain the temperature of the reaction between 0-5°C. The mixture was stirred at 0-5°C for 30 minutes and then neutralised by addition of solid sodium bicarbonate. The resulting solution was then added portionwise to a solution of copper cyanide (2.42 g, 27.0 mmol) and potassium cyanide (3.65 g, 56.1 mmol) in water (25 ml) at 70°C. The mixture was stirred at 70°C for 30 minutes, allowed to cool and then extracted with toluene (2 times). The combined extracts were washed with water and brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by flash chromatography on silica (cluant 5% ethyl acetate/ 95% pet. ether) to give an orange solid identified as 4-bromo-2,6-dimethylbenzonitrile (3.2 g, 68%).

9B. 4-Cyano-3,5-dimethylbenzoic acid

4-Bromo-2,6-dimethylbenzonitrile (3.20 g, 15.2 mmol) was reacted following the method of Example 6 to give a tan solid identified as 4-cyano-3,5-dimethylbenzoic acid (1.5 g, 56%).

Example 10

25

10A. 4-Amino-2-chloro-benzoic acid methyl ester

Acetyl chloride (2.5 ml) was added drop-wise to a solution of 2-chloro-4-cyano-benzoic acid (2.22 g, 12.94 mmol) in methanol (75 ml) while stirring. The mixture was heated at reflux for 18 h, cooled and concentrated in vacuo. The residue was taken up in ethyl acetate, washed with saturated NaHCO₃ and brine and concentrated in vacuo to give a beige solid identified as 4-amino-2-chloro-benzoic acid methyl ester (2.32 g, 97%).

10B. 2-Chloro-4-cyano-benzoic acid methyl ester

4-Amino 2-chloro-benzoic acid methyl ester (5.00 g, 26.94 πunol) was reacted following the method of Example 9A to give a pale orange solid identified as 2-chloro-4-cyano-benzoic acid methyl ester (2.62 g, 50%).

COP-GE TESTA O Spectroma mont incress, by TRY NETTERS COS P.S. 1981 (Gramme) (1991) (1

Empfangszeit 14. Feb. 16:14

Lithium hydroxide (1.12 g, 26.69 mmol) was added to a solution of 2-chloro-4-cyano-benzoic acid methyl ester (2.60 g, 13.29 mmol) in dioxan/water (4.1, 100ml). The mixture was stirred at room temperature for 3h and concentrated in vacuo. The residue was partitioned between 1N hydrochloric acid and chloroform and the organic layer was washed with brine and concentrated in vacuo. The residue was recrystallised from a mixture of dioxan and pet. ether to give a pale orange solid identified as 2-chloro-4-cyanobenzoic acid (2.33 g, 97%).

Example 11.

.

the district of the Valentian and present of the State Control of the State of the

Empfansszeit 14 Fet. 16:14

11A. 3-Fluoro-4-methylbeuzoic acid methyl ester

5

20

3-Fluoro-4-methylbenzoic acid (5.0 g, 32.4 mmol) was reacted following the method of Example 8B to give a brown oil identified as 3-fluoro-4-methylbenzoic acid methyl ester (4.5 g, 83%).

11B. 4-Bromomethyl-3-fluorobenzoic acid methyl ester

3-Fluoro-4-methylbenzoic acid methyl ester (4.5 g, 26.6 mol) was reacted following the method of Example 4A to give a yellow oil identified as 4-bromomethyl-3-fluorobenzoic acid methyl ester (2.7 g, 41%).

11C. 4-Azidomethyl-3-fluorobenzoic acid methyl ester

Sodium azide (609mg) was added to a solution of 4-bromomethyl-3-fluorobenzoic acid methyl ester (2.1 g, 8.5 mmol) in DMF (30ml). The mixture was stirred for 18h, diluted with ethyl acetate, washed with water and brine and concentrated in vacuo to give a colourless oil identified as 4-azidomethyl-3-fluorobenzoic acid methyl ester (1.78 g, 100%).

11D. 4-Aminomethyl-3-lluorobenzoic acid methyl ester

Hydrogen was passed through a degassed solution of 4-azidomethyl-3-fluorobenzoic acid methyl ester (2.11 g, 10 mmol) in methanol containing 10% palladium on carbon for 2 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo to give a colourless oil identified as 4-aminomethyl-3-fluorobenzoic acid methyl ester (1.51 g, 83%).

25 11E. 4-(tert-Butoxycarbonylamino-methyl)-3-fluorobenzoic acid methyl ester

To a solution of 4-aminomethyl-3-fluorobenzoic acid methyl ester (1.5 g, 8.2 mmol) in dichloromethane (20 ml) were added di-tert-butyl dicarbonate (2.3 g, 11 mmol) and triethylamine (1.4 ml, 10 mmol). The mixture was stured for 18h, washed with 0.3M KHSO₂ and brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 10% EtOAc/pet. ether) to give a white solid identified as 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid methyl ester (1.4 g, 60%),

11F. 4-(tert-Butoxycarbonylamino-methyl)-3-fluorobenzoic acid

To a solution of 4-(tert-Butoxycarbonylamino-methyl)-3-fluorobenzoic acid methyl ester (640 mg, 2.25 mmol) in dioxan (40 ml) was added 1N NaOH (4.5 ml, 4.5 mmol). The mixture was stirred for 18 h, diluted with ethyl acetate, washed with 1N KHSO4, water and brine and concentrated in vacuo to give a white solid identified as 4-(tert-butoxycarbonylamino-methyl)-3-fluorobenzoic acid (608 mg, 100%).

Example 12

4-Cyano-3-ethylbenzoic acid. 10

12A. 4-Bromo-2-ethylbenzonitrile

4-Bromo-2-ethylaniline (12.5 g, 62.5 mmol) was reacted following the method of Example 9A to give a pale brown oil identified as 4-bromo-2ethylbenzonitrile (7.66 g. 58%).

12B. 4-Cyano-3-ethylbenzoic acid

4-Bromo-2-ethylbenzonitrile (7.55 g, 35.9 mmol) was reacted following the method of Example 6 to give a pale brown solid identified as 4-cyano-3ethylbenzoic acid (4.34 g, 69%)

Example 13

अध्येत्वतंत्रः वनार्वे १५) सन्धेतः स्टब्स्य १०११ । १९४५ वर्षः ११ वर्षः ६८ - ५८ १ वर्ष १ वर्ष सर्वेत्तवीत्। हिन्दोरका व्यवस्थात्र रावानुष्टर

Emplangszeit 14. Peb. 16:1

13A. 4-Cyano-2-methoxybenzoic acid methyl ester

4-Amino-2-methoxybenzoic acid methyl ester (4.59 g, 25.33 mmol) was reacted following the method of Example 9A to give a pale yellow solid identified as 4-cyano-2-methoxybenzoic acid methyl ester (2.58 g, 53%).

13B. 4-Cyano-2-methoxybenzeic acid

4-Cyano-2-methoxybenzoic acid methyl ester (2.68 g, 15.52mmol) was reacted following the method of Example 10C to give a white powder identified as 4-cyano-2-methoxybenzoic acid (2.60 g, 95%).

Example 14

4-(3-Methyl-4-(piperazine-1-carbonylaminomethyl)benzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine hydrochloride

14A: 4-(3-Methyl-4-cyanobenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepinc

Thionyl chloride (5 ml, 68.55 mmol) was added to a stirred suspension of 4-cyano-3-methylbenzoic acid (1.43 g, 8.90 mmol) in dichloromethane (20 ml). The mixture was heated at reflux for 2 h, cooled to room temperature and concentrated in vacuo. The residue was azeotroped with dichloromethane then dissolved in dichloromethane 20 ml. The resulting solution was slowly added to a stirred solution of 5,6,7,8-tetrahydrothieno[3,2-b]azepine (1.36 g, 8.90 mmol) and triethylamine (3.70 ml, 26.54 mmol) in dichloromethane (30 ml). The mixture was stirred at room temperature for 24 h, washed with 1M KHSO₄, saturated NaHCO₃ and brine, then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 25% EtOAc/pet. ether) to give a brown solid identified as 4-(3-methyl-4-cyanobenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine (1.70 g, 71%).

*PRODES OF THE PROPERTY OF THE REPORT OF METERS OF A STATE OF A SERVICE OF THE RESERVE OF THE PROPERTY OF T

14B: 4-(4-Aminomethyl 3-methylbenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine

Cobalt(II) chloride hexaligidrate (2.84 g, 11.94 mmol) was added to a solution of 4-(3 methyl-4-cyanobenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine (1.70 g, 5.70 mmol) in methanol (70 ml) at 0°C. Sodium borohydride (2.22 g, 58.68 mmol) was added portion wise at 0°C and the mixture was stirred at 0°C for 30 min then at room temperature for 2 h. Saturated ammonium chloride was then added and the mixture was stirred for 30 min then concentrated in vacuo. The residue was azeotroped with toluene then extracted with chloroform. The extracts were washed with brine and concentrated in vacuo to give a white solid identified as 4-(4-aminomethyl-3-methylbenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine (1.12 g, 65%).

14C: 4-(4-(4-(tert-Butyloxycarbonyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine

1,1'-Carbonyldimidazole (234 mg, 1.45 mmol) was added to a solution of 4-(4-aminomethyl-3-methylbenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine (400 mg, 1.33 mmol) and DIEA (0.3 ml, 1.72 mmol) in DME (20 ml) and the mixture was stirred at room temperature for 30min. tert-Butyl piperazine-1-carboxylate (281 mg, 1.50 mmol) was added and the mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue was taken up in chloroform and the solution was washed with 1M KHSO₄ and brine, then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 75% EtoAc/pet. ether) to give a white solid identified as 4-(4-(4-(tert-butyloxycarbonyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine (588 mg, 86%).

14D: 4-(3-Methyl-4-(piperazine-1-carbonylaminomethyl)benzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine hydrochloride

A solution of 4-(4-(tert-butyloxycarbonyl)piperazine-1-carbonyl-aminomethyl)-3-methylbenzoyl-5,6,7,8-tetrahydrothieno[3,2-b]azepine (588 mg, 1.15 mmol) in 4N HCl/dioxan (10 ml) was stirred at room temperature for 30 min then concentrated in vacuo. The residue was dissolved in acetonitrile/water and lyophilised to give a white solid identified as 4-(3-methyl-4-(piperazine-1-carbonylaninomethyl)benzoyl)-5,6,7,8-tetrahydrothieno[3,2-b]azepine hydrochloride(893 mg, 76%).

The collection of the property of the state of the collection of the state of the s

Empfangszeit 14: Feb. 16:14

20

¹H NIMR: d₆-DMSO δ 1.60-1.74 (2H, m), 1.82-1.94 (2H, m), 2.17 (3H, s), 2.86-2.95 (2H, m), 2.96-3.10 (4H, m), 3.35-3.45 (2H, m), 3.50-3.64 (4H, m), 4.16 (2H, s), 6.26 (1H, br s), 6.85-7.10 (4H, m), 7.24 (1H, br s), 9.28 (1H, br s) ppm.

 $MS: [M+H]^+ = 413.2$

Example 15

10 5-(4-(4-Cyclopropylmethylpiperazine-1-carbonylaminomethyl)-3-methylbenzodiazepine benzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

15A: 5-(4-Cyanó-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b]-

Thionyl chloride (1.8 ml, 27 mmol) was added to a stirred suspension of 4-cyano-3-methylbenzoic acid (1.29 g, 8.0 mmol) in tolucne (25 ml). The mixture was heated at reflux for 2 h cooled to room temperature and concentrated in vacuo. The residue was azeotroped with tolucne then dissolved in dichloromethane (10 ml). The resulting solution was added to a stirred suspension of 1-methyl-4,10-diliydropyrazolo[5,4-b][1,5]benzodiazepine (1.6 g, 8 mmol) and triethylamine (1.4 ml, 10 mmol) in dichloromethane (15 ml). The mixture was stirred overnight at room temperature then concentrated in vacuo. The residue was partitioned between chloroform and 0.3M KHSO₄. The aqueous phase was extracted with chloroform/2-propanol (80:20). The combined organic phases were washed with sat. NaHCO₃ and brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (chant 5% methanol/chloroform) to give a pale yellow solid identified as 5-(4-cyano-3-methylbenzoyl) 1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]-benzodiazepine (2.4 g, 87%).

Turbles 14 15:16 N 1 May some on the trible of the Art Car Conference benefit if the interest and the conference of the Art Conferen

Empfansszeit 14 Feb. 16:14

25.

15B: 5-(4-Aminomethyf-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

Cobalt (II) chloride hexallydrate (1.59 g, 6.7 mmol) was added to an ice-cold solution of 5-(4-cyano-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (1.15 g, 3.35 mmol) in methanol (35 ml). Sodium borohydride (1.27 g, 33.5 mmol) was added portion wise at 0°C and the mixture was stirred at RT for 1 h, then quenched with 1M KHSO₄ and concentrated in vacuo. The aqueous residue was diluted with 1M KHSO₄ (40ml) and fittered through Cellife filter agent. The filtrate was washed with diethyl ether (2 × 50 ml) then besified with 2 M NaOH and extracted with chloroform. The organic phase was dried over Na₂SO₄ and concentrated in vacuo to give a pale brown solid identified as 5-(4-aminomethyl-3-methylbenzoyl)-1-methyl-4,10-lihydropyrazolo[5,4-b][1,5]benzodiazepine (745 mg, 64%).

15C: 5-(4-(4-(tert-Butyloxycarbonyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4 10-dihydropyrazolo[5,4-b][1,5]-benzodiazepine

1,1'-Carbonyldiimidazole (76 mg, 0.47 mmol) was added to a solution of 5-(4-(aminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (150 mg, 0.43 mmol) and DIEA (0.1 ml, 0.57 mmol) in DMF (10 ml). The solution was stirred for 30 min, tert-butyl piperazine-1-carboxylate (91 mg, 0.49 mmol) was added and stirring was continued for 72 h. The mixture was concentrated in vacuo and the residue was taken up in chloroform. The solution was washed with water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 100% EtOlac then 10% methanol/EtOAc) to give a white solid identified as 5-(4-(4-(tert-butyloxycarbonyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]-benzodiazepine (160 mg, 66%)

15D: 1-Methyl-5-(3-methyl-4-(piperazine-1-carbonylaminomethyl)benzoyl)-4,10-dihydropyrazo[[5,4-b][1,5]benzodiazepine hydrochloride

A solution of 5-(4-(4-(telt-butyloxycarbonyl)piperazine-1-carbonylaminoniethyl)-3-methylbenzoyl)-1-methyl-4,10-

"the terms of the state of the

.20

dihydropyrazolo[5,4-b][1,5]benzodiazepine (160 mg, 0.29 mmol) in 4N HCl/dioxan (15 ml) was stirred at room temperature for 30 min then concentrated in vacuo. The residue was azeotroped with diethyl ether-to give a white solid identified as 1-methyl-5-(3 methyl-4-(piperazine-1-carbonylamino-methyl)-benzoyl)-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine hydrochloride (130 mg, 90%).

15E: 5-(4-(4-Cyclopropylmethylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10 diliydropyrazolo[5,4-b][1;5]benzodiazepine

To a solution of 1-methyl-5-(3-methyl-4-(piperazine-1-carbonylaminomethyl)-benzoyl) 4,10-dihydropyrazolo[5,4-b][1,5]-benzodiazepine hydrochloride (100 mg, 0.20 mmol) and triethylamine (0.5 ml, 3.59 mmol) in THF (10 ml) were added cyclopropanecarboxaldehyde (14 mg, 0.20 mmol) and sodium cyanoborohydride (15 mg, 0.24 mmol) and the resulting mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue was dissolved in ethyl acetate and the resulting solution was washed with saturated NaHCO₃, water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 10% methanol/EtOAc) to give a white solid identified as 5-(4-(4-cyclopropylmethylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (35 mg, 35%).

¹H NMR: d₄-MeOH δ 0.14 (2H, q, J=4.7Hz), 0.51-0.59 (2H, m), 0.82-0.95 (1H, m), 2.15 (3H, s), 2.28 (2H, d, J=6.7Hz), 2.52 (4H, t, J=4.9Hz), 3.43 (4H, t, J=4.9Hz), 3.80 (3H, s), 3.95 (1H, d, J=14.4Hz), 4.23 (2H, s), 5.78 (1H, d, J=14.6Hz), 6.61-6.74 (2H, m), 6.99 (2H, s), 7.03 (1H, s), 7.05-7.14 (1H, m), 7.19-7.24 (2H, m) ppm.

MS: $[M+H]^{+} = 514.3$.

30

10

1.5

20

Example 16

5-(4-(4-Benzylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolu[5,4-b][1,5]benzodiazepine

5

To a solution of 1-methy -5-(3-methyl-4-(piperazine-1-carbonylamino-methyl)-benzoyl)-4,10-dhydropyrazolo[5,4-b][1,5]benzodiazepine hydrochloride (100 mg, 0.20 mmol) and triethylamine (0.5 ml, 3.59 mmol) in THF (10 ml) were added benzaldenyde (21 mg, 0.20 mmol) and sodium cyanoboro-hydride (15 mg, 0.24 mmol) and the resulting mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue was dissolved in ethyl acetate and the resulting solution was washed with saturated NaHCO₃, water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica sel (chuant 5% methanol/EtOAc) to give a white solid identified as 5-(4-(4 benzylpiperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-lihydropyrazolo[5,4-b][1,5]benzodiazepine (37 mg, 34%).

H NMR: δ 2.10 (3H, s); 2.36-2.48 (4H, m), 3.29-3.44 (4H, m), 3.48-3.51 (2H, m), 3.76 (3H, s), 3.96 (1H, d, J=14.6Hz), 4.22-4.28 (2H, m), 4.61-4.68 (1H, m), 5.88 (1H, d, J=14.6Hz), 6.45 (1H, s,) 6.62-6.74 (2H, m), 6.82-6.96 (3H, m), 6.98-7.11 (2H, m), 7.19-7.3 (5H, m) ppm.

MS: $[M+H]^{+} = 550.2$

25[.]

Example 17

15

20

5-(4-(4-(3-Hydroxybenzyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

17A: 3-(tert-Butyldimethylsilyloxy)toluene

tert-Butyldimethylsilyl chloride (3.00 g, 22.00 minol) was added to a solution of m-cresol (2.00g, 18.00mmol) and triethylamine (4 ml, 28.7 mmol) in dichloromethane (50 ml) at 0°C. The mixture was stirred at room temperature for 24h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 10% EtOAc/pet. ether) to give a colour-less oil identified as 3-(tert-butyldimethylsilyloxy)toluene (3.60 g, 88%).

17B: 3-(tert-Butyldimethylsilyloxy)benzyl bromide

N-Bromosuccinimide (2.90 g, 16.20 mmol) and AIBN (266 mg, 1.62 mmol) were added to a stirred solution of 3-(tert-butyldimethylsilyloxy)toluene (3.60 g, 16.20 mmol) in carbon tetrachloride (120 ml) and the mixture was heated at refflix for 24h, then allowed to cool to room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant cyclolicxane) to give a colourless oil identified as 3-(tert-butyldimethylsilyloxy)benzyl-bromide (2.45 g, 50%).

17C: tert-Butyl 4-(3-hydroxybenzyl)piperazine-1-carboxylate.

Sodium hydride (406 mg, 60% dispersion in oil, 10.15 mmol) was

25 added portionwise to a stirred solution of tert-butyl piperazine-1-carboxylate in

DMF (50 ml) at 0°C. The mixture was allowed to warm to room temperature

over 1h, then a solution of 3-(tert-butyldimethylsilyloxy)benzyl bromide (2.44

g, 8.10 mmol) in DMF (10 ml) was added dropwise and the mixture was stirred

at room temperature for 24 h. Water was added and the mixture was stirred for

30 min then poured into EtOAc. The organic phase was washed with saturated

market and the second and the above process of the rest of the res

Empfangszeit 14 Feb. 16:14

NaHCO₃ and brine, then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 40% EtOAc/pet. ether) to give a light brown oil identified as tert butyl 4-(3-hydroxybenzyl)piperazine-1-carboxylate (2.00 g. 84%).

17D: 1-(3-Hydroxybenzyl)piperazine dihydrochloride

A solution of tert-butyl 4 (3-hydroxybenzyl)piperazine-1-carboxylate (1.94 g, 6.60 mmol) in 4N HCl/dioxan (10ml) was stirred at room temperature for 30 min then concentrated in vacuo. The residue was triturated with diethyl ether to give a white solid identified as 1-(3-hydroxybenzyl)piperazine dihydrochloride (1.10 g, 63%).

17E: 5-(4-(4-(3-Hydroxybenzyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

1,1'-Carbon Idiim dazole (15 mg, 0.09 mmol) was added to a stirred solution of 5-(4 (amin omethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo [5,4-b][1,5]benzodiazepine (31 mg, 0.09 mmol) and DIEA (0.1 ml 0.57 mmol) in DMF (5 ml). The solution was stirred for 1h, 1-(3-hydroxybenzyl)piperazine dihydrochloride (27 mg, 0.10 mmol) was added and stirring was continued at room temperature for 24 h. The mixture was concentrated in vacua and the residue was taken up in EtOAc. The solution was washed with saturated NaHCO3 and brine, then concentrated in vacua. The residue was purified by flash chromatography on silica gel (eluant 20% methanol/EtOAc) to give a white solid identified as 5-(4-(4-(3-hydroxybenzyl)-piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo [5,4-b][1,5]benzodiazepine (45 mg, 90%).

¹H NMR: δ 2.15 (3H, s), 2.41 (4H, t, J=4.7Hz), 3.40 (4H, t, J=4.7Hz), 3.46 (2H, s), 3.80 (3H, s), 3.97 (1H, d, J=14.6Hz), 4.22 (2H, s), 4.90 (1H, m), 5.78 (1H, d, J=14.6Hz), 6.62-6.79 (5Ε, m), 6.99 (2H, s), 7.03-7.27 (6H, m) ppm.

MS: $[M+H]^+ = 566.1$

hors of the televial Modern authorist TEP (S), profession factors of each and contained they between high manners and the contained they between high manners and the contained they between the contained the contained they between the contained the contai

Empfansszeit 14 Feb. 16:14

Example 18
5-(4-(4-(3-H) droxymethylbenzyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

18A: tert-Butyl 4-(3-(methyloxycarbonyl)benzyl)piperazine-1-carboxylate

Methyl 3-(bromomethylbenzoate) (1.23 g, 5.37 mmol) was added to a stirred solution of tert-butyl piperazine-1-carboxylate (1.00 g, 5.37 mmol) and triethylamine (1.50 ml, 10.74 mmol) in dichloromethane (20 ml). The solution was stirred at room temperature for 24h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant EtOAc) to give a white solid identified as tert-butyl 4-(3-(methyloxycarbonyl)benzyl)-piperazine-1-carboxylate (1.55 g, 86%).

18B: tert-Butyl 4-(3-carboxybenzyl)piperazine-1-carboxylate

Lithium hydroxide monollydrate (339 mg, 9.27 mmol) was added to a solution of test-butyl 4-(3-(methyloxycarbonyl)benzyl)piperazine-1-carboxylate (1.55 g, 4.63 mmol) in THF (10 ml) and water (2 ml). The solution was stirred at room temperature for 24 h then acidified to pH 5 with 0.3 M KHSO₄ and extracted successively with chloroform and dichloromethane. The combined extracts were concentrated in vacuo to give a white solid identified as test-butyl 4-(3-carboxybenzyl)piperazine-1-carboxylate (1.09 g, 74%).

18C: tert-Butyl 4-(3-(hydroxymcthyl)benzyl)piperazine-1-carboxylate

Isobutyl chloroformate (0.47 ml, 3.64 mmol) was slowly added to an ice-cold solution of tert-butyl 4-(3-carboxybenzyl)piperazine-1-carboxylate (1.06 g, 3.31 mmol) and V-methylmorpholine (0.80 ml, 7.28 mmol) in THF (15 ml). The solution was stirred at 0°C for 45 min and then filtered. The filtrate was added to an ice-cold solution of sodium borohydride (313 mg, 8.27 mmol) in water (10 ml). The stirred mixture was allowed to warm to room

रिमाण्डाक तक एक अंतर्गाहरू है। तक किराहरू के अंतर्गाहरू है पार्ट के अंतर्गाहरू के अपने के बहुत महाराम देशक एक व - कुलाब्बर मानव अक्षा स्थापना है। वार्ट

25

temperature over 2 h and then concentrated in vacuo. The residue was taken up in EtOAc and the solution was washed with water and brine then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant EtOAc) to give a white solid identified as tert-butyl 4-(3-(hydroxymethyl)benzyl)piperazine-1-carboxylate (230 mg, 23%).

18D: 1-(3-(Hydroxymethyl)benzyl)piperazine dihydrochloride

A solution of tert-butyl 4 (3-(hydroxymethyl)benzyl)piperazine-1-carboxylate (230mg, 0.75mmol) in 4N HCl/dioxan (10ml) was stirred at room temperature for 45min then concentrated in vacuo. The residue was azeotroped with toluene to give a white solid identified as 1-(3-(hydroxymethyl)benzyl)-piperazine dihydrochloride (158 mg, 75%).

18E: 5-(4-(4-(3-Hydroxymethylbenzyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-*b*][1,5]benzodiazepine

1,1'-Carbonyldimidazole (20 mg, 0.12 mmol) was added to a solution of 5-(4-(aminomethyl)-3 methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (35 mg, 0.10 mmol) in DMF (3 ml). The solution was stirred for 1 h, a solution off 1-(3-(hydroxymethyl)benzyl)piperazine dihydrochloride (31 mg, 0.11 mmol) and DIEA (54 μl, 0.30 mmol) in DMF (2 ml) was added and the mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue taken up in chloroform and the solution was washed with brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 7% methanol/chloroform) to give a white solid identified as 5-(4-(4-(3-hydroxymethylbenzyl)piperazine-1-carbonylaminomethyl)-3 methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (27 mg, 50%).

¹H NMR: δ 2.00 (3H, s), 2.32-2 36 (4H, m), 3.32-3.45 (4H, in), 3.46 (2H, s), 3.63 (3H, s), 3.91 (1H, d) J=14.6Hz), 4.10-4.20 (1H, m), 4.66 (2H, s), 5.28-5.29 (1H, m), 5.80 (1H, d, J=14.3Hz), 6.50-7.30 (15H, m) ppm.

MS: $[M+I-I]^{+} = 580.3...$

14

Example 19

1-Methyl-5-(3-methyl-4-(4-(4-picolyl)piperazine-1-carbonylaminomethyl)-benzoyl)-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

To a solution of 1-methyl-5-(3-methyl-4-(piperazine-1-carbonylamino-methyl)-benzoyl)-4.10-dihydropyrazolo[5,4-b][1,5]benzodiazepine hydrochloride (100 mg, 0.20 mmol) and triethylamine (0.5 ml, 3.59 mmol) in THF (10 ml) were added 4-pyridirecarboxaldehyde (21 mg, 0.20 mmol) and sodium cyanoborohydride (15 mg, 0.24 mmol) and the resulting mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue was dissolved in ethyl acetate and the resulting solution was washed with saturated NaHCO₃, water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 10%-30% methanol/EtOAc) to give a white solid identified as 1-methyl-5-(3-methyl-4-(4-(4-picolyl)piperazine-1-carbonylaminomethyl)benzoyl)-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (33 mg, 30%).

¹H NMR: δ 2.13 (3H, s), 2.34-2 49 (4H, m), 3.29-3.47 (4H, m), 3.76 (3H, s), 3.96 (1H, d, J=14.8Hz), 4.25-4.27 (2H, d, J=4.7Hz), 4.50-4 60 (1H, m), 5.90 (1H, d, J=14.4Hz), 6.25 (1H, s), 6.63-6.71 (2H, m), 6.84 (2H, s), 6.92 (1H, s), 7.00-7.12 (2H, m), 7.25 (5H, s), 8.53 (2H, d, J=5.9Hz) ppm.

MS: $[M+H]^+ = 551.1$

25

10

entendent et ek vid varian och militerio konstitution vid på et anskeret et marketet etter entender stem ble Te dienter et vis et vor ble et den kommer i det i

Empfanøszeit 14.Feb. 16:14.

Example 20

5-(4-(4-(2-Hydroxyethyl)piperazine-1-carbonylaminomethyl)-3methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine

5 .

1,1'-Carbonyldimidazole (20 mg, 0.19 minol) was added to a solution of 5-(4-(aminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (31 mg, 0.09 mmol) in DMF (3 ml). The solution was stirred at room temperature for 1h, a solution of 1-(2-hydroxyethyl)-piperazine (13 mg, 0.10 mmol) in DMF (2 ml) was added and stirring was continued for 72 h. The solution was concentrated in vacuo and the residue was partitioned between chloroform and brine. The organic layer was separated and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 7% methanol/chloroform) to give a white solid identified as 5-(4-(4-(2-hydroxyethyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (22 mg, 48%).

¹H NMR: δ 2.09 (3H, s), 2.42-2.59 (6H, m), 2.91-3.01 (1H, m), 3.33-3.62 (6H, m), 3.67 (3H, s), 3.93-3.98 (1H, m), 4.20-4.23 (2H, m), 5.00-5.03 (1H, m), 5.84-5.90 (1H, m), 6.64-7.25 (9H, m) ppm.

MS: $[M+H]^{+} = 504.2$

Sept. 12. 15. 15. 15. 15. Notice after a deficient of Miles to Otto Secretary to Repair of the conference of the confere

Empfansszeit 14-Reb. 16:14

50

Example 21

1-Methyl-5-(3-methyl-4-(4-(3-(methylthio)propyi)piperazine-1-carbonylaminomethyl)benzoyb 4,10-dihydropyrazolo[5,4-h][1,5]-benzodiazepine

To a solution of 1-methyl 5-(3-methyl-4-(piperazine-1-carbonyl-aminomethyl)-benzoyl)-4,10-dillydropyrazolo[5,4-b][1,5]benzodiazepine hydrochloride (00 mg, 0.20 mmol) and triethylamine (0.5 ml, 3.59 mmol) in THF (10 ml) were added 3-(methylthio)propionaldehyde (21 mg, 0.20 mmol) and sodium cyanoborohydride (5 mg, 0.24 mmol) and the resulting mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue was dissolved in ethyl acetate and the resulting solution was washed with saturated NaHCO₃, water and brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 20% methanol/EtOAc) to give a white solid identified as 1-methyl-5-(3-methyl-4-(4-(3-methylthio)propyl)piperazine-1 carbonylaminomethyl)benzoyl)-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine (41 mg, 38%).

¹H NMR: δ 1.63-1.80 (3 H, m), 2.04-2.12 (4H, m), 2.33-2.42 (6H, m), 2.48 (2H, t, J=6.7Hz), 3.29-3.39 (4H, m), 3.71 (3H, s), 3.93 (1H, d, J=14.4Hz), 4.12-4.30 (2H, m), 4.57-4.70 (1H, m), 5.85 (1H, d, J=14.6Hz), 6.44 (1H, s), 6.59-6.71 (2H, m), 6.83-6.88 (2H, m), 6.92-7.08 (2H, m), 7.14-7.27 (2H, m) ppm.

MS: $[M+H]^+ = .548.0$

over the time of the companies of the deliver of the contract of the contract

Empfansszeit 14. Fieb - 16:14

Example 22

5

15

5-(4-(4-(2-Aminocthyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydrapyrazolo[5,4-b][1,5]benzodiazepine dihydrochloride

22A: Beuzyl 4-(2-hydroxyethy) piperazine-1-carboxylate

Benzyl chloroformate (3.40 ml, 24.00 mmol) was slowly added to an ice-cold stirred solution of 1-(2-liydroxyethyl)piperazine (2.60 g, 20.00 mmol) and DIEA (7.0 ml, 40.0 mmol) if dichloromethane (75 ml). The mixture was allowed to warm to room temperature and stirred for 24 h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 6% methanol/chloroform) to give a colourless gum identified as benzyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (4.80 g, 91%).

22B: Benzyl 4-(2-bromoethyl)piperazine-1-carboxylate

Carbon tetrabromide (7.2% g, 21.80 mmol) was added to an ice-cold stirred solution of benzyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (4.80 g, 18.20 mmol) in dichloromethane (50 ml). The solution was stirred for 5 min, triphenylphosphine (5.95 g, 22.70 mmol) was added, and the mixture was allowed to warm to room temperature and stirred for 3 h. Silica gel was added and the solvent was removed in acuo. The residue was purified by flash chromatography on silica gel (eluant 50% EtOAc/pet. ether) to give a colourless gum identified as benzyl 4-(2-bromoethyl)piperazine-1-carboxylate (3.45 g, 58%).

22C: Benzyl 4-(2-(tert-butyloxycarbonylamino)ethyl)piperazine-1-carboxylate

Benzyl 4-(2-bromoethyl) inperazine-1-carboxylate (3.45 g, 10.55 mmol) was added to an ice-cold saturated solution of ammonia in ethanol (60 ml). The

rote di 14 mm de Si Chigama di rote di Riche. Il sul di del 11 mm de la compania di la Chiga di April 2011 de la Chiga de la Chiga di April 2011 de la Chiga de la

Empfansszeit 14 Reb. 16:14

mixture was allowed to warm to foom temperature and stirred for 4 h, then concentrated in vacuo. The residue was triturated with diethyl ether. The resultant solid was suspended in dichloromethane (75 ml) and triethylamine (2.25 ml, 16.00 mmol). The suspension was cooled to 0°C and ditert-butyl dicarbonate (2.40 g, 11.00 mmol) was added. The mixture was allowed to warm to room temperature and stirred for 24 h then concentrated in vacuo. The residue was taken up in EtOAc. The solution was washed with saturated NaHCO₃ and brine, then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 3% methanol/chlorofonn) to give a yellow gum identified as benzyl 4-(2-(tert-bu yloxycarbonylamino)ethyl)piperazine-1-carboxylate (2.60 g, 68%).

22D: tert-Butyl 2-(1-piperaziny) ethylcarbamate

Hydrogen was passed through a degassed solution of benzyl 4-(2-(tert-butyloxycarbonylamino) ethyl)piperazine-1-carboxylate (2.60 g, 7.16 mmol) in methanol (50 ml) containing 10% palladium on carbon (500 mg) for 2 h. The reaction mixture was filtered through Celite® and the filtrate was concentrated in vacuo to give a yellow gum identified as tert-butyl 2-(1-piperazinyl)ethyl-carbamate (1.60 g, 97%).

22E: 5-(4-(4-(2-(tert-B)tyloxycarbonylaminoethyl)piperazine-1-carbonyl-aminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine

1,1'-Carbonyldinaidazole (25 mg, 0.15 mmol) was added to a solution of 5-(4-(aminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (31 mg, 0.09 mmol) and DIEA (0.1 ml, 0.57 mmol) in DMF (5 ml). The solution was stirred for 1h, tert-butyl 2-(1-piperazinyl)-ethylcarbamate (22 mg, 0.10 mmol) was added and stirring was continued at room temperature for 24 h. The mixture was concentrated in vacuo and the residue was taken up in EtOAc. The solution was washed with saturated Na-HCO3 and brine, then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (el ant 20% methanol/EtOAc) to give a white solid identified as 5-(4-(4-(2-(tert-butyloxycarbonylaminoethyl)piperazine-1-carbonylaminomethyl)-3 methyl benzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (44 fpg, 81%).

ANTERIOR CONTRA DE LA PROPERCIO DE LA CONTRA DEL CONTRA DE LA CONTRA DEL CONTRA D

20

35

22F: 5-(4-(4-(2-Aminoethyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydrepyrazolo[5,4-b][1,5]benzodiazepine dihydrochloride

A solution of 5-(4-(4-(2-(krt-butyloxycarbonylaminoethyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepire (42 mg, 0.07 mmol) in 4N HCl/dioxan (5 ml) was stirred at room temperature for 30 min then concentrated in vacuo. The residue was dissolved in acetonitrile/water and lyophilised to give a white solid identified as 5-(4-(4-(2-aminoethyl)piperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]benzodiazepine dihydrochloride (37 mg, 92%).

¹H NMR: δ 2.17 (3H, s), 3.30-3 35 (4H, m), 3.41-3.50 (1H, m), 3.56-3.72 (4H, m), 4.00 (3H, s), 4.04 (1H, s), 4.26 (2H, s), 4.83-4.89 (2H, m), 5.88 (1H, d, J=15Hz), 6.83-6.84 (2H, m), 6.92-7.13 (4H, m), 7.15-7.28 (1H, m), 7.36 (1H, d, J=7.9Hz), 7.96 (1H, s) ppm.

MS: $[M+H]^+ = 503.5$

20 Example 23

1-Methyl-5-(3-methyl-4-(4-methylperhydro-1,4-diazepine-1-carbonylaminomethyl)benzoy) -4,10-dihydropyrazolo[5,4-b][1,5]-benzodiazepine

1,1'-Carbonyldiimidazolo (37 mg, 0.23 minol) was added to a solution of 5-(4-(aminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo-[5,4-b][1,5]benzodiazepine (75 mg, 0.22 mmol) in DMF (2 ml). The solution was stirred for 1h, a solution of i-methylhomopiperazine (27 mg, 0.24 mmol) and DIEA (31 ing, 0.24 mmol) in DMF (1 ml) was added and stirring was con-

The Control of Southern of Control of the Control of Co

tinued for 24 h. The mixture was concentrated in vacuo and the residue was purified by chromatography on silica gel (cluant 30/2/1 – 1/1/1 chloroform/methanol/concentrated ambionia) to give a white solid identified as 1-methyl-5-(3-methyl-4-(4-methylicrhydro-1,4-diazepine-1-carbonylamino-methyl)benzoyl)-4,10-dillydropy azolo[5,4-b][1,5]benzodiazepine (38 mg, 36%).

¹H NMR: δ 1.80-1.99 (2H, m), 2.10 (3H, s), 2.35 (3H, s), 2.51-2.69 (4H, m), 3.39 (2H, t, J=5.9Hz), 3.45-3.68 (2H, m), 3.63 (3H, s), 3.95 (1H, d, J=14.6Hz), 4.23 (2H, t, J=4.2Hz), 4.65=4.75 (1H, m), 5.85 (1H, d, J=14.6Hz), 6.65-6.75 (2H, m), 6.76-6.38 (2H, m), 6.90-7.09 (2H, m), 7.11-7.22 (2H, m) ppm.

MS: [M+H]+=488.2

15 Example 24

10

5-(4-(4-(2-Hydroxyethyl)piper zine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine

24A: 5-(4-Cyano-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-z][1,4]diazopine

Thionyl chloride ().6 ml, 2.00 mmol) was added to a suspension of 4-cyano-3-methylbenzoic acid (322 mg, 2.00 mmol) in toluene (10 ml). The mixture was heated at reflux for 2 h allowed to cool and concentrated in vacuo. The residue was azeotroped with toluene and then taken up in dichloromethane (5 ml). The solution was added slowly to a stirred solution of 1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine (400 mg, 2.00 mmol) and triethylamine (0.35 ml, 2.50 mmol) in dichloromethane (5 ml). The mixture was stirred at room temperature or 24 h then concentrated in vacuo. The resi-

Toris of the entry Robinson and Anthony Configurations of the first of the entry of the first of the first of the entry of

due was purified by flash chromi ography on silica gel (eluant 5% methanol/chloroform) to give at orange solid identified as 5-(4-cyano-3-methylbenzoyl)-1-methyl-4,10-dihydro yrazolo 4,5-c]pyrido[2,3-b][1,4]diazepine (500 mg, 73%).

24B: 5-(4-Aminomethyl-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[3-b][1,4]diazepine

Cobalt(II) chloride hexah, drate (690 mg, 2.90 mmol) was added to an ice-cold stirred solution of 5-(4-wano-3-hethylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pycido[2, -b][1,4 diazepine (500 mg, 1.45 mmol) in methanol (15 ml). Sodium borol varide (570 mg, 15.00 mmol) was added portion wise and the mixture was stared at room temperature for 1h. 1M KHSO₄ was added, the methanol was removed in vacuo, and the aqueous residue was filtered through Celite. The filtrate was washed with diethyl ether, basified to pH12 with 2M sodium hydroxid, and extracted with chloroform. The chloroform extracts were washed with rine and concentrated in vacuo to give a pale orange solid identified as 5-(4-athinomethyl-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2, -b][1,4 diazepine (400 mg, 79%).

24C: 5-(4-(4-(2-Hydroxyethyl) iperazine-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10 lihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine

1,1'-Carbonyidium dazold (20 mg, 0.12 mmol) was added to a solution of 5-(4-aminomethyl-3-methylb azoyl)-1-methyl-4,10-dihydropyrazolo[4,5-c]pyrido[2,3-b][1,4]diazepine (3 mg, 0 to mmol) in DMF (3 ml). The solution was stirred for 1h, a solution of 1-(2 hydroxyethyl)piperazine (13 mg, 0.10 mmol) and DIEA (18 µl, 0.10 m nol) in DMF (2 ml) was added and the mixture was stirred at room temperature for 24 h then concentrated in vacuo. The residue taken up in chloroform and the solution was washed with brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cluant 7% methanol/chloroform) to give a pale yellow solid identified as 5-(4-(4-(2-bydroxyethyl) iperazi c-1-carbonylaminomethyl)-3-methylbenzoyl)-1-methyl-4,10-dihydropyrazolo [4,5-c]pyrido[2,3-b][1,4]diazepine (29 mg, 58%).

35

25) 2 122 14 10 10 32 Segrent of the ment reports of the first to 1 to 4 to 5 to 1 1 20 Section of Performance of the Control of the Control

Empfanaszeit 14 Feb. 16:14

H NMR: δ 2 42 (3H, br s), 2.44 2.60 (7H, m), 3.20-3.40 (4H, m), 3.55-3.65 (2H, m), 3.79 (3H, s), 3.85-4.00 (H, m), 4.26 (2H, br s), 4.88 (1H, br s), 5.80-5.95 (1H, m), 6.60 (1H, br s), 6.80-7.30 (6H, m), 8.00 (1H, s) ppm.

5. MS: $[M+H]^{\dagger} = .505.2$

15

Example 25
4-(2-Cyclopropyl-ethyl) pipera inc-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dibydro-3Pl-2,3,4,,-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

25A: 3-Methyl-4-(3-methyl-4,1)-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbduyl)-b uzonitzile

Thio yl chloride (\$\frac{1}{2}\$ 8 ml, \$\frac{1}{2}\$ 1.00 m nol) was added to a suspension of it—Cyano-2-methylbenzoic acid (619 mg, 3 91 mmol) in toluene (30 ml). The mixture was heated at reflux for 2h, allowed to cool and concentrated in vacuo. The residue was azeotroped with toluene and then taken up in dichloromethane (25ml). The resulting solution was added to a stirred solution of 1-methyl-4,10-dihydropyrazolo[5,4-b][1,5]ben paiazep ne (706 mg, 3.53 mmol) and triethylamine (0.70ml, 5.02mmol) in dichloromethane (25ml). The mixture was heated at reflux for 18h and cooled. The mixture was diluted with dichloromethane and washed with 0.3 M KH\$O₄, saturated NaHCO₃ and brine then concentrated in vacuo: The residue was purified by flash chromatography on silica gel (cluant ethyl acetate) to give an ff-white solid identified as 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 letraaza benzo[f]azulene-9-carbonyl)-benzonitrile (1.06 g, 87%).

The court of the companies and the contract of the contract of

Empfansszeit 14. Reb. 16:14

25B: (4-Aminomethyl-2-methyl phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azuleu 9-yl)-methanouc

Cobalt(II) chloride hexalt drate (1.45 g, 6.09 mmol) was added to a stirred solution of 3 methyl-4-(3 methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-ber conitrile (1.04 g, 3.03 mmol) in methanol (50 ml). Sodium borohydride (1.16 g 30.66 rumol) was added portion-wise and the mixture was stirred at room term brature for 3 h. 0.3 M KHSO₄ was added and the mixture was concentrated in acuo. The residue was diluted with saturated NaHCO₃ and extracted with chic oform. The chloroform extracts were washed with brine, concentrated in vacua and freeze dried to give an off-white solid identified as (4-aminomethyl-2-dethyl-phenyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]zzulen--yl)-methanone (475 mg, 45%).

25C: 4-(2-Cyclopropyl-ethyl)-liperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-31,2,3,4,1-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

1,1'-Carbonyldiim dazold (29 mg, 0.18 mmol) was added to a solution of (4-anniomethyl-2-methyl-ph nyl)-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetrauza-benzo[f]azulen-9-yl)-m thanone (60 mg, 0.17 mmol) in DMF (3 ml).

The solution was stirred for 1 h, solution of 1-(2-Cyclopropyl-cthyl)-piperazine (39 mg, 0.17 mmol) and DIEA (98 μl, 0.55 mmol) in DMF (1 ml) was added and the mixture was cirred at room temperature for 18 h. The mixture was diluted with ethyl aceta e and washed with 5% KHCO₃, water and brine and concentrated in vacuo. The residue was purified by flash chròmatography on silica gel (cluant 100/1 /1 chloroform/methanol/concentrated ammonia) to give a white solid (dentif ed as 4-(2-cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl 4-(3-nethyl-4, 0-dihydro-3H-2,3,4,9-tetrauza-benzo[f]azulene-9-carboryl)-benzylamide (51 mg, 56%).

30 ~ ¹H IMR: δ 0.01-0.09 (2H, m) 6 42-0.44 (2H, m), 0.62-0.66 (1H, m), 1.34-1.40 (2H, m), 2.29 (3H, s) 2.31-1.42 (6H, m), 3.31-3.35 (4H, m), 3.66 (3H, s), 3.97 (1H, d, J=14.6Hz), 4.20 (2H, d, J=5 4Hz), 4.39-4.41 (1H, m), 4.89-4.94 (1H, m), 5.83 (1H, d, J=14.6Hz) 5.56-7.26 (8H, m)

35 MS: $[M+H]^+ = 528.7$

10.

Twinking 14 to 4d.) Nother at month reported states that the tracked stilled by panels providing organization and the providing of the providi

Empfangszeit 14 Reb. 16:14

Examples 26 - 150

The following compounds were prepared using methods analogous to those described above.

5 - Examples 26 - 35

1861	a	${f R}^{f l}$	R			MS: [M+H] ⁺
26	1	Cl	CH ₃			447.3
27	2	CI 🌡	CH ₃			461.3
28	1°	Me'	CH ₂	CH2CH2	CH ₃	469.3
29	1	Ме	CH ₂	сн(сн	CH₂CH₃	483.3
30	1.	Me.	CH ₂			467.3
31	1,	Cl				510.3
32	1	-Me	СН		— он	533.3
33	1	Me	CH.	l C	ОН	523.2
34	1	Me	СН		©O ₂ Et	539.3

अनुसन्दर्भ । अनुसन्दर्भ विकास के कार्य है कि प्रति । जिल्ला के स्वरंभ के अनुसन्दर्भ के अनुसन्दर्भ के अनुसन्दर्भ अनुसन्दर्भ कार्य कार्य कार्य के अनुसन्दर्भ के अनुसन्दर्भ के अनुसन्दर्भ के अनुसन्दर्भ के अनुसन्दर्भ के अनुसन्दर

Empfangszeit 14 Feb. 16:14 k

BEST AVAILABLE COPY

		•	•			· · .	. 22						
•				ន		\mathbb{R}^1	and a second second	R ⁴			59	MS: [M+H	I †
		35	,	1	!	Me		CE	I ₂ 5	H_2	OH	457.2	
	X A A A	aple	es 36		31.		o de la constanta de la consta				\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	R ⁴	
			A ³ .		\mathbf{A}^6	-		8			b	\mathbb{R}^4	MS: [M+H] ⁺
	36		CH		ŅΗ	[1	-Me			3	H	474.1
	37		CH	il	ŅF	ı	- 17	-Me	1 . 1		3	CH ₂ CH(CH ₃)CH ₂ CH ₃	544.3
	38		CH		ŅI.	[14	-Me			3	CH ₂ C(CH ₃) ₃	544.3
. •	39		CH		ŅΕ	Ţ.	T.	-Me			3	CH	528.3
	40		CH		17-	Me		-Me			1	CH ₂	514.3
	41		N		TVF	· .		∫-M ∈			2	CH ₂ OH	680.2
. •	42	•	CH		Ŋ-	Me ∵	7	І-Ме			.2	CH ₂ —OH	594.3
	43		CH		ŅĒ	<u> </u>	1	I-M¢		ŀ	3	CH_S	570.3
	44	::	CH.		Ņŀ	I		I-Me		Ŀ	2	CH ₂	556.3
				-	,								

Sent de 141 et 3 Nebreau e dongs L'int qu'anness bista strata : e i it qu'

Empfansszeit 14 Feb. 16:14

						60		
 		A ³	AG A	8 ~ .		b	R¹	MS: [M+)AT *
•	45	CH.	NH .	-Me		3 .	CO₂Et	600.3
	46	CH	TH I	-Me		2	CH ₂	586:3
	47	N	I/IHI]	-Ме		2	CH ₂ CH ₂ NH ₂	504.1
	48	N	NEI	-Ме		2	CH ₂ CH ₂ CH ₂ NH ₂	518.3
	49	CH.	NH.	M-Me		2	CH ₂	571.4
	50	N	NH	M-Me		2.		572.3
	51	CH	NH	I -CH₂J	h	2	CH₂CH₂OH	580.2
5	Example His H ₃ C		-126	H			N R ⁴	
			R4			• .	M\$: [M+H	1
		52	1 - 1	_		· 	460.2	
		53	+ ++	15	#	<u> </u>	474.2	
		54		121	- 11	.	488.2	
		55		CM2CH	-115	· ·	502.3	•
		50	 	CII2CH	-11		516.3	
Finn	*	. •	CH ₂	illi:				M. kestuatosia, aluto se
Cur		· (Had: 10.1.				W	a the second to the

rus de persona de la Marina a como respecta de la contra d La contra de la como de la como de la contra d

mpfangszeit 14 Fieb. 16:14

							62						··· :
·				.	\mathbb{R}^4		·		•	М\$: [M+H]	+		
			71		CH ₂		•			634.2			
	_	· · · · · · · · · · · · · · · · · · ·	72		CH ₂		z	-		634.2			
			73		CH ₂			Z-0		634.2			
	_ ·		74		CH ₂	0)	-			540.3			
	~		75		GH ₂	0)	, toi	· ·	n	570.2			
			76	- 1	CH ₂	S	_CO₂M	5		614.2			• · · · · · · · · · · · · · · · · · · ·
•			77		CH ₂	S	Ol	_		586.3			
•		## FULL PROPERTY OF THE PROPER	·78		CH ₂	CI	_CO₂M	0)		648.2			
			79		- CH ₂	CI	<u></u>			620.2	· · · · · ·		
•	in.a. ir.a. Empfanss					7	\	in a second	55 1 × 1 × 1	1010000	a p _e tico, s	9 (61.)	*1

		-			-		
· ·					63		
			R⁴				MS: [M+H] ⁺
	80		CH ₂		-	•	538.2.
	81		CH ₂	g z			553.1
	82		€H ₂				540.2
	83		СН	N	CO _z Et		629.2
	84	;	CH ₂	S	√ OH		587.3
	85		CH ₂		CO₂Et		599.2
	86	1,	CHz	N			551.3
	87		ÇH₂−	N==	CO ₂ Et		609.1
	88		CH ₂	N	/—ОН }		581.3
	•						

Empfangszeit 14-Feb. 16:14

-		آآآآ	!E	iii	: R		
		1				•	
	1					•	
	· į	· 1	,	,	:. I		
	į	: !			64	•	
ſ	<u> </u>		i		.	_	MC.
	1	• :	\mathbb{R}^4				MS:
					<u> </u>		[M+H] ⁺
		·	-	/P :	. 2 1		
	89	i	CH	K.	·		516.3
	•	1		CH ₃		-	
		;	CH ₂				
	90	1		/_ -c	Нз		530.2
				P		ļ	
		:	-	9			
	٠.		Cl-l ₂	K ·			
	01	7.					592.2
	91						
,					~LI .		
			<u>.</u>		CH3 ··	<u> </u>	
	92	-	CH ₂ C	II ₂ CO ₂ (H ₃ .	•	546.3
. •	93	· .	CH₂C	II ₂ CO ₂ I			532.1
	94		CH ₂ C	II₂CH₂€	O₂ĈH₃		560.2
	95		1	II ₂ CN			513.4
	96	Ť	CH₂C	iki ·		:	529.2
		1	1				
			CH ₂				5.50
	97	1:	1)\—			571.2
		.	1	1 r	Ю		
] <u> </u>				•	
•			CH2	温.			
	98	i :	引 	`o			572.2
		:		. :	i o		
•		T:	CH ₂		CH ₃		1 : : : : :
	99		4	`o			546.3
			i		o ·	:	
	Bannan.	1	1	-			
•			·		.		1
	•						
	٠.	11	1	阅 .		· · · ·	

Empfansszeit 14. Feb. 16:14


		· i	וֹיִריייר וּ	···	ı	- Eru
		_				
			· , 5	:		
			:			
	';	· * ·				Ţ.
•				C		
ĺ	1:	ا		65		
						MS:
.]		\mathbf{R}^4			· .	[M+H] ⁺
		· j				[YAY : TY]
	' '					
1	.					
	100	CI-I2		/		608.3
ļ	100	:	0			000.5
A		- 1	. 1	L · .		
				٠ - · ·		
			. !	N		
		· - i				
	101	CH ₂	1			609.3
		2 2	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			609.3
[•
ĺ				0.		
		÷	O .			
Ì		CH ₂				
	102					557.3
	1		H	7		
``	1 1 4					
	103	CH ₂		CH ₃		600
. [103		0			560.3
:]	· · i ;			CH ₃		
٠,٠		: !!				
٠. ا			,9			
	104	CH ₂	K			572.2
. [) O			
	105	CH ₂ C	₂ CH ₂)	H_2		517.3
	106	CUC	TATO	₂ CH ₃) ₂		. £50.2
· ·	100		1211(2CF13J2		559.3
		CH ₂	N. 1			
)Ñ=-;			
-	107	-	K) :		573.2
) . · ·		
		(1)		<u> </u>		
		CH ₂	<i>[/:</i>]			
	108		N→			5577
			(人) ii			557.3
	109	Cla	CTT	H ₂ OH		
	1.07	U1124	12CF12	CI ₂ OII		532.3
:						
٠.	. /					

To be to the to hadronic took to the second of the second

Empfanøszeit 14.Feb. 16:14

entropiesta presente proprio in in Stelland Labora i tipic in marche in propincia de propincia de la companya d

Empfansszeit 14. Feb. 16:14



CH2CH2OH

CH₂C I₂OH

CH21

рн

502.1

501.3

533,3

a regional esta del man appropriata del merche del propriata de la composición del composición de la composición del composición de la composición del composición del composición del composición del composición

Empfansszeit 14 Reb. 16:14

134

135

136

137

ΝH

Examples 142 - 149

THE CAPETER PLANT OF THE CONTROL OF THE CAPETER PARTY OF THE CAPETER PAR

Empfansszeit 14 Reb. 16:14

, 66 KBA T2\					 			
~. ·	•		\mathbb{R}^3		: /	0 1	MS: [M+H] ⁺	
	142		CH			9	- 514.3	÷
	143	-	CH.			0	528.3	
	144		F			9	518.3	* :
	145		F		• • • • • • • • • • • • • • • • • • • •		532.1	
	146	4	Cl				534.5	
	147		Cl				548.6	
	148		CH	$\mathbb{C}\mathrm{H}_3$			EH ₂	
	149		OC	¥13			544.4	
H ₃ C	amiter: Mi		6:14		0	,	R ⁴	

150 CH ₂ S14.3		() - I		-1		71		 -		Pro-	•
				\mathbb{R}^4							MS: [M+H] ⁺	·
	1	150		 CH ₂		-	-	·			514.3	

Example 151 In vitro Testin

Compounds were stayed to determine their ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, the compounds of the invention duse significant inhibition of cellular activation at concentrations of 30 µM or less. Preferred compounds cause significant inhibition at concentrations of 500 nM

0 Example 152

Tablet for Oral Administration

Tablets containing 100 mg of the compound of Example 15 as the active agent are prepared from the following:

1 11 1 3 3 3 1 1 1	161 · · · · · · · · · · · · · · · · · ·
Compound of Example 15	200.0 g
Corn starch	71.0 g
Hydroxypropylcellumse	18.0 g
Carboxymethylcellupse calcium	13.0 g
Magnesium stearate	3.0 g
Lactose	195.0 g
Total	500.0 g

The materials are lended and the pressed to give 2000 tablets of 250 mg, each containing 100 mg of the compound of Example 15.

The forgoing deminstrates that the compounds according to the present invention act as antagorists at the vascoressin V_{in} receptor and accordingly they may find utility as tharmaceutical agents for the treatment of conditions such as primary dysmetorrhoea, pre-term labour, hypertension, Raynauld's disease, brain oederna, notion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liker circhosis and congestive heart failure.

mines to track to be bream or constitute not propagate and the research of the constitution of the research page in the propagate and the constitution of the constitu

Empfansszeit 14 Heb. 16:14

The scope of the present invention is further defined in the following claims.

ers and the entry free book a committee and a recommendation in the first of the first of the committee of t

Empfangszeit 14 Feb. 16:14

1. A compound according to general formula 1, or a pharmaceutically acceptable salt firereof

wherein:

. 3

- G¹ is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;

of 32 of the distribution of the property of t

Empfansszeit 14 Reb., 16:14

phenyl;

મ ∗લીકારા અધ્યાવચીઓ

- Ar is selected from optionally substituted thicnyl and optionally substituted

Empfansszeit 14. Reb. 16:14

and CF₁:

- a is 1 or 2, b is 1, 2 or 3 c is 1 or 2, d is 1, 2 or 3; e is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2; provided that: > not more than one of A A and A 10 is NH, N(CH₂)dR⁷ or S;

- A⁷ and A¹¹ are not both simultaneously N;

- neither A⁷ nor A¹¹ is N f one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;

- if A¹⁰ is not CH=CH—then one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S or one of A^7 and A_1^{11} is N;

- not more than one of A#, A15 and A16 is NH, N-CH3 or S

- A¹² and A¹³ are not both simultaneously N;

- if one of A^{14} , A^{15} and A^{16} is NH, N–CH₃ or S then A^{12} and A^{13} are both C and

- one of A¹⁴, A¹⁵ and A¹⁶ is NH, N+CH₃ or S or one of A¹² and A¹³ is N, wherein said compound is selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-(2-Cyclopropyl-ethyll-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dihydro-3H,2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclopropylinethyl-phperazine 1-carboxylio acid 3-methyl-4-(3-methyl-

4,10-dihydro 3H 2,3,4,9 tetraaza-benzolif]azulene-9-carbonyl)-benzylamide;

- 4-Cyclopropylinethyl-perazine 1-carpoxylic acid 3-fluoro-4-(3-methyl-

4,10-dihydro-31-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2methyl-4-(3-methyl-4,10 dihydro-3H-2,3,4,9-tetranza-benzo[f]azulene-9-

carbonyl)-benzylamide;

30

- 4-(3-Methyl-butyl)-pip razine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide;

- 4-Cyclopentylmethyl-pperazine-l-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide

- 4-Cyclopropylmethyl-mperazine 1-carboxylic acid 3-chloro-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyi)-benzylamide;

4-Cyclobutylmethyl-pilerazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-

dihydro-3H-2,3,49-tetra za-benzo flazulenc-9-carbonyl)-benzylamide;

- 4-Cyclobuty methyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetradza-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-(2-Cyclopropyl-ethyl) piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-BH-2,3,4,9 etranza-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Pentyl-piperazine-1-duboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetranza-benzw[f]azulene-9-carbonyl)-benzylamide; - 4-Hexyl-piperazine-1-chrboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tchaza-benz [f]azulene-9-carbonyl)-benzylamide; - (R)-4-(2-Mcthyl-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 etraaza-benzo[[f]azulene-9-carbonyl)-benzylamide; 10 - 4-(2-Ethyl-butyl)-piper zine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulenc-9-carbonyl)-benzylamide; - 4-(2-Methyl-but-2-enyl-piperazine-1-darboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Cyclobuty methyl-pigerazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Cyclobuty methyl-pigerazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetradza-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Cyclobutylinethyl-pillerazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetralza-benzo[f]azulenc-9-carbonyl)-benzylamide; - 4-Cyclopropylmethyl-pperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Cyclobutylmethyl-pifferazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-ternaza-benza [f]azulene-9-carbonyl)-benzylamide; - 4-Cyclopropylmethyl-mperazine 1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-25 dilıydro-3H-2,3,4,9-tetra za-benzo[f]azıllene-9-carbonyl)-benzylamide; - 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide; - 4-Cyclopropylinethyl-uperazine 1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo [f]azulene-9-carbonyl)-benzylamide; 30 - 4-Cyclobutylırıethyl-pilerazine-1-carbexylic acid-3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo fazulene-9-carbonyl)-benzylamide.

2. A pharmaceutical composition comprising a compound according to claim 1 as an active agent.

ni pero sultania di su seria del pero de la compania del compania de la compania de la compania del compania de la compania del la compania del la compania de la compania de la compania del la compania de la compania del la compania de

:77

5. A pharmaceutical composition according to Claim 2 or 3 for treatment of male erectile dysfunction.

6. A pharmaceutical composition according to Claim 2 or 3 for treatment of pre-term labour, hypertension, Raynauld's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.

7. The use of a compound according to general formula 1, or a pharmaceutically acceptable sale thereof

$$\begin{array}{c|c}
G^{1} & R^{3} \\
\hline
 & R^{2} \\
\hline
 & N \\
 & (CH_{2})_{a} \\
\hline
 & N \\
 & (CH_{2})_{b}
\end{array}$$


20 wherein:

-G' is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;

the State of the second of the second of the state of the second of the

Empfansszeit 14 Reb. 16:14,





- A¹ is selected from CH, CH(OH), NH, N-alkyl, O and S;
 - A² is selected from CH₃, CH(OH), C(=0) and NH;
 - A³ is selected from S, NH, N-alkyl, -CH=CH- and -CH-N-;
 - A⁴ and A⁵ are each selected from CH and N;
- 10 A6 is selected from CH, NH, N-alkyl and O;
 - A⁷ and A¹¹ are selected from C and N;
 - A⁸ and A⁹ are selected from CH, N, NH, N(CH₂), R⁷ and S;
 - A¹⁰ is selected from -CH=CH-, CH, N, NH, N(CH₂)_dR⁷ and S;
 - A¹² and A¹³ are selected from N and C;
- 15 ... A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
 - X1 is selected from O and NH;
 - R1, R2 and R3 are each elected from H alkyl, O-alkyl, F, Cl and Br;
 - R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thenyl, optionally substituted furyl, optionally s
- tuted pyridyl, optionally substituted pyriolyl, optionally substituted pyrazolyl, optionally substituted in dazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_R, CH₂-CH\(\hat{C}H_2-R^8\), -CH₂-C\(\hat{C}H_2-R^8\), -CH₂-C\(\hat{C}H_2-R^8\), -(CH₂)_B-

CH(OH)-(CH₂)_h-R⁸, -(CH₂)_i-O-(CH₂)_j-R⁸ and CH₂ $\stackrel{\square}{\longrightarrow}$ R⁶

25 - R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂)_f-Ar;

and Software directly in the contract of the c

Empfansszeit 14 Feb. 16:14

- R⁷ is selected from H, akyl, optionally substituted phenyl, E, OH, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;

- R⁸ is selected from H, akyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted pyral zolyl, optionally substituted pyral zolyl, optionally substituted inidazolyl, optionally substituted oxazolyl, optionally substituted oxazolyl, optionally substituted thiazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, CH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl,
- N(alkyl)-acyl N₃, CO₂H CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
 - Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
- 15 a is 1 or 2, b is 1, 2 or 3, c is 1 or 2, d is 1, 2 or 3; c is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2; provided that
 - not more than one of A, A and A to is NH, N(CH₂)_dR or S;
 - A⁷ and A¹¹ are not both simultaneously N;
- 20 neither A⁷ nor A¹¹ is N four of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
 - if A¹⁰ is not -CH=CH, then one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S or one of A⁷ and A¹¹ is N;
 - not more than one of All4, All and All6 is NH, N-CH3 or S

hour in the Hilliam is the first in the

- A¹² and A¹³ are not both simultaneously N;
- if one of A¹¹, A¹⁵ and A¹⁶ is NH, N-CH₃ or S then A¹² and A¹³ are both C;
 - one of A¹⁴, A¹⁵ and A¹⁵ is NH, N-CH₃ or S or one of A¹² and A¹³ is N, for the manufacture of a pharmaceutical composition for treatment of primary dysmenorrhoea.

8. The use of a compound according to general formula 1, or a pharmaceutically acceptable salithereof

Empfanæszeit 14 Feb. 16:14

wherein:

- G' is selected from a group according to general formula 2, a group according to general formula 3 a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;

- A' is selected from CH, CH(OH), NH, N-alkyl, O and S;

- A² is selected from CH, CH(OH), C(=O) and NH;

- A³ is selected from S, NH, N-allyf, -CH=CH- and -CH=N-; - A⁴ and A⁵ are each selected from CH and N;

पाची भागिकता है।


Empfangszeit 14 Reb

- A6 is selected from CHINH, Walkyl and O;
- A⁷ and A¹¹ are selected from G and N;
- A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S;
- A¹⁰ is selected from -CH=CH_H, CH, N, NH, N(CH₂)_dR⁷ and S;
- $5 A^{12}$ and A^{13} are selected from N and C;
 - A¹⁴, A¹⁵ and A¹⁶ are selected from NH, N-CH₃, S, N and CH;
 - X' is selected from O and NH;
 - R^1 , R^2 and R^3 are each selected from H alkyl, O-alkyl, F, Cl and Br;
- R⁴ is selected from H, akyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thirnyl, optionally substituted furyl, optionally substituted pyrazolyl, optionally substituted pyrazolyl, optionally substituted im dazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, -(CH₂)_eR⁸, CH₂-CH₂-CH₂-CR⁸, -CH₂-C=C-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂)_e-CH₂-CH₂-R⁸, -(CH₂-CH₂-R⁸)_e-CH₂-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-R⁸, -(CH₂-R⁸)_e-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-CH₂-
- 15 CH(OH)-(CH₂)₁₁-R³, -(CH₂)₁-Q-(CH₂)₁-R³ and CH₂
 - R⁵ and R⁶ are independently selected from alkyl, Ar and -(CH₂),-Ar;
 - R⁷ is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, Nli-alkyl, N(alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃,
- R⁸ is selected from H, akyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrazolyl, optionally substituted oxazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally sub-
- 25 stituted isothiazolyl, F, OH, livdroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH₂, NH-alkyl, N(alkyl)₂, 1-porolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N_B, CO₂H, CO, alkyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
 - Ar is selected from optionally substituted thienyl and optionally substituted phenyl;
 - a is 1 or 2, b is 1, 2 or 3 c is 1 or 2, d is 1, 2 or 3; c is 1, 2, 3 or 4; f is 1, 2 or 3 and g, h, i and j are all independently 1 or 2; provided that:
 - not more than one of Al, A and A is NH, N(CH2)dR7 or S;

・・・特。四漢、和(4**) に・1

35 - A7 and A11 are not both simultaneously N;

30



- not more than one of A, A, and A is NH, N-CH3 or S;
- 5 A¹² and A¹³ are not both simultaneously N;
 - if one of A¹⁴; A¹⁵ and A¹⁶ is NH, N-CH₃ or S then A¹² and A¹³ are both C; and
- one of A¹⁴, A¹⁵ and A¹⁶ is NH, N-CH₃ or S or one of A¹² and A¹³ is N, for the manufacture of a pharmaceutical composition for treatment of pre-term labour, hypertension, Rasmauld's disease brain ocdema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis or congestive heart failure.
- 9. The use according to Claim 7 or 8, wherein at least one of R¹, R² and 15 R³ is H and at least one is not H
 - 10. The use according to any one of Claims 7-9, wherein one of \mathbb{R}^1 , \mathbb{R}^2 and \mathbb{R}^3 is selected from an alkyl group, an O-alkyl group, F. Cl and Br and the others are H.
 - 11. The use according to any one of the Claims 7 10, wherein X is
- 12. The use according to any one of the Claims 7 11, wherein a is 1 25 and b is 2.
 - 13. The use according to any one of the Claims 7 12, wherein G^1 is a group according to general formula 3.
- 30 14. The use according to Claim 13, wherein c is 2.
 - 15. The use according to Claim 13 or 14, wherein A is CH₂ and A² is NH.
- 35 16. The use according to Claim 13 or 14, wherein A is NH or N-alkyl and A² is C(=O).

CONTRACTOR OF THE PROPERTY OF

- 17. The use according to Claim 13 or 14, wherein A³ is S and A⁴ and A⁵ are both CH.
- 18. The use according to any of Claims 13 17, wherein A^3 is CH=CH- and A^4 and A^5 are both CH.
 - 19. The use according to any of Claims 13 17, wherein A³ is –CH=N-and A⁴ and A⁵ are both QH.
 - 20. The use according to any of Claims 13 17, wherein A³ is CH-CH-, A⁴ is CH and A⁵ is N
- 21. The use according to any of Claims 7 12, wherein G¹ is a group according to general formula 6 or 7
 - 22. The use according to Claim 21, wherein A3 is S and A4 and A5 are both CH.
- 23. The use according to Claim 21, wherein A³ is -CH=CH- and A⁴ and A⁵ are both CH.
 - 24. The use according to Claim 21, wherein A³ is -CH-N- and A⁴ and A⁵ are both CH.
 - 25. The use according to Claim 21, wherein A³ is -CH=CH-, A⁴ is CH and A⁵ is N.
- 26. The use according to any one to Claims 7 12, wherein G¹ is a group according to general formula 4 or 6.
 - 27. The use according to Claim 26, wherein A6 is NH.
- 28. The use according to Claim 25 or 27, wherein A⁸ is NH or N-35 (CH₂)_d-R⁷.

据引起 *** 1·参广

Notes of Other W

Empfansszeit 14 Peb. 16:14

- 29. The use according to Claim 28, wherein A? is N and A10 is CH.
- 30. The use according to Claim 7 or 8, wherein one of R¹, R² and R³ is selected from an alkyl group, an 3-alkyl group, F, Cl and Br and the others are H and X' is NH.:
 - 31. The use according to any one of Claims 7 or 8, wherein one of R', R^2 and R^3 is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X^1 is NH alis 1 and b is 2.
 - 32. The use according to Claim 7 or 8, wherein G' is a group according to general formula 6, A4, A5 and A10 are all CH, A6 is NH, A7 and A11 are both C, A8 is N-(CH2)d-R7 and A9
- 33. The use according to Claim 7 or 8, wherein R' is an alkyl group, an O-alkyl group, F, Cl or Br, R' and R' are both H, X' is NH, a is 1, b is 2, G' is a group according to general formula 6, A^4 , A^5 and A^{10} are all CH, A^6 is NH, A^7 and A^{11} are both C, A^4 is N-(CH₂)_d-R and A^9 is N.
- 34. The use according to Claim 7 or 8, wherein said compound is se-20 lected from the group consisting of:
 - 4-Cyclopropylmethyl-pperazile-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3;4,9 tetraizin benzo fjazulene-9-carbonyl)-benzylamide,

 - 4-(3,3-Dimethyl-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetrauzn-benzo f]azulene-9-carbonyl)-benzylamide,
 4-(3-Methylsulfanyl-proppyl) piperazine-1-carboxylic acid 2-methyl-4-(3-

 - methyl-4,10-dihydro-3H 2,3,4,9 tetraszd-benzo[f]azulene-9-carbonyl)benzylamide,
 - 4-(2-Cyclopropyl-ethyll-piperazine-1-darboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetrazza-benzolf]azulene-9-carbonyl)-benzylamide.

 - 4-Cyclopropylmethyl-perazine-1-carboxylic acid 3-methyl-4-(3-methyl-

 - 4,10-dihydro-3H-2,3,4,9 tetranza benzolf azulene-9-carbonyl)-benzylamide,
 -- 4-Cyclopropylmethyl-perazine-1-carboxylic acid 3-fluoro-4-(3-methyl-

事。1974年

4,10-dihydro-311-2,3,4,9 tetranza-benzo fjazulene-9-carbonyl)-benzylamide,

Miles as a roll it is a soil

30

- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2, methyl-4-(3-methyl-4,10 dihydip-3H-2,3,4,9-tetraaza-benzo[f]azulene-9carbonyl)-benzylamide,

- 4-(3-Mcthyl-butyl)-pipgrazine il carboxylic acid 2-methyl-4-(3-methyl-4,10)

dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-p perazine 1-cartoxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclohexylmethyl-pilerazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-31-1-2,3,4,9 tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclopropylmethyl-pperazine 1-car oxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza-benzo []azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylinethyl-piterazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-

dihydro-3H-2,3,4,9-tetraliza-berzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-pijerazing-I-carboxylic acid 2-methyl-4-(3-methyl-4,10-

dihydro-3H-2,3,4,9-tetraliza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-(2-Cyclopropyl-ethyll-piperazine-1-darboxylic acid 3-methyl-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzolflazulene-9-carbonyl)-benzylamide.

- 4-Pentyl-piperazine-1-earboxy ic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzp[f]azulene-9-carbonyl)-benzylamide,

- 4-Hexyl-piperazine-l-duboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzp[f]azulenc-9-carbonyl)-benzylamide,

- (R)-4-(2-Methyl-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzolf]azulene-9-carbonyl)-benzylamide.
- 4-(2-Ethyl-butyl)-piper zine-li carboxylic acid 2-methyl-4-(3-methyl-4,10-

dihydro-3H-2,3,4,9-tetraliza-benzo[f]azujene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-eny)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dihydro-3H-2,3,4,9 tetraaza-benzoffjazulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraliza-beigzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylinethyl-pilerazine l-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraliza-benzo[f]azulene-9-carbonyl)-benzylamide.

- 4-Cyclobutylmethyl-piperazine 1-carb xylic acid 2-fluoro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide,
-4-Cyclopropylinethyl-perazine-1-carboxylic acid 2-fluoro-4-(3-methyl-

4,10-dihydro 3H-2,3,4,9 tetraazi benzo fazulene-9-carbonyl)-benzylamide; 35

- 4-Cyclobutylmethyl-piperazine l-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzelf]azu elle-9-carbonyl)-benzylamide, 4-Cyclopropylmethyl-riperazine 1-carrioxylic acid 2-ethyl-4-(3-methyl-4,10-

dihydro-3H-2,3,4,9-tetra ka-benko[f]azulenc-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-pinerazine il-carbaxylic acid 2-chloro-4-(3-methyl-4,10-

dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclopropylmethyl-piperazire 1-carpoxylic acid 2-chloro-4-(3-methyl-

4,10-dihydro-3H2,3,4,9 chrazz benzolf azulene-9-carbonyl)-benzylamide, and

- 4-Cyclobutylinethyl-piterazine learboxylic acid 3-methoxy-4-(3-methyl-4,10-dilydro-3H-2,3,4,9 etraaza-benzo []azulene-9-carbonyl)-benzylamide.

35. The use of a compound selected from the group consisting of: - 4-(3,3-Dimethyl-butyl) piperazine-1-cii boxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 letrazza-benzolf azulene-9-carbonyl)-benzylamide, - 4-(2-Cyclopropyl-ethyl-piper zime-1-darboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-31,2,3,4,9 tetranza-benzo []azulene-9-carbonyl)-benzylamide. - 4-Cyclopropylmethyl-reperazine 1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dilydro-311-2,3,4,9 tetraazin benzolf azulenc-9-carbonyl)-benzylamide, - 4-Cyclopropylmethyl-perazine 1-can oxylic acid 3-fluoro-4-(3-methyl-20 4,10-dihydro-3H-2,3,4,9 retraaza benzo f azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxynaethyl-c elopio ylmethyl)-piperazine-1-carboxylic acid 2methyl-4-(3-methyl-4,1d dillyd b 3H-2, 4,9-tetraaza-benzo[f]azulene-9carbonyl)-benzylamide, - 4-(3-Methyl-tutyl)-pip razine carboxylic acid 2-methyl-4-(3-methyl-4,10-

diliydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide, -4-Cyclopentylmethyl-pperazine 1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraazii-benzo flazulene-9-carbonyl)-benzylamide.

- 4-Cyclohexylmethyl-pillerazine 1-carboxylic acid 2-methyl-4-(3-methyl-

4,10-dilydro 3H-2,3,4,9 tetrazzi benzo fjazulene-9-carbonyl)-benzylamide.

- 4-Cyclopropylmethyl-perazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-311-2,3,4,9 cetraazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-311-2,3,4,9 cetraazine-2011) azulene-9-carboxyl)-benzylamide,

- 4-Cyclobutylmethyl-pilerazine i -carbyxylic acid 3-chloro-4-(3-methyl-4,10--dihydro-3H-2,3,4,9-tetra za-benze [f]azrilene-9-carbonyl)-benzylamide,

- 4-Cyclobutylinethyl-pilerazing-i -carboxylic acid 2-methyl-4-(3-methyl-4;10dihydro-3H-2,3,4,9-tetraliza-benze[f]az lene-9-carbonyl)-benzylamide,

म्मार का अन्तर कर प्रतिविद्यालका के स्टिस्ट्रिक कि स्टिस्ट्रिक कि स्टिस्ट्रिक के स्टिस्ट्रिक के स्टिस्ट्रिक के स्टिस्ट्रिक के स्टिस्ट्रिक के स्टिस्ट्रिक के स्टिस्ट्रिक कि स्टिस्ट्रिक के स्ट्रिक के स्ट्रिक के स्ट्रिक के स्

30

UZ/14 10:25 PAA +40 40 400

.81

- 4-(2-Cyclopropyl-ethyl piperazine-1-chroxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-BH-2,3,4,9 etraaza-benzo[[]azulenc-9-carbonyl)-benzylamide, - 4-Pentyl-piperazine-1-cirboxylic acid 2 methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzylf]azulcie-9-carbonyl)-benzylamide, - 4-Hexyl-piperazine-1-c rboxyl cacid 2 methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetranza-benz) [f]azulene-9-carbonyl)-benzylamide, - (R)-4-(2-Methyl-butyl) pipeinzine-1 carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H 2,3,4,9 fetrazza benzo Fjazulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piper zine l-garboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azu ene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaza benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-pijerazine l-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetra za-benzo[f]azu ene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-piperazine j-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetra za-benzo[f]azu ene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-pinerazing - carbaxylic acid 2-fluoro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclopropylinethyl-perazine 1-carroxylic acid 2-fluoro-4-(3-inethyl-4,10-dihydro-3H2,3,4,9 ctrazza-benzo[t]azulene-9-carbonyl)-benzylamide, -4-Cyclobutylmethyl-pi erazine li-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetrasza-benzy[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclopropylmethyl-pperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetra za-benzylf]azulene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-pitterazine-l-carbexylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetral za-benzo[f]azurene-9-carbonyl)-benzylamide, - 4-Cyclopropylmethyl-pperazine 1-car oxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 letraaza benzo fjazulene-9-carbonyl)-benzylamide, and - 4-Cyclobutylmethyl-pitterazine l-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraza-benzo tjazulene-9-carbonyl)-benzylarnide, for the manufacture of a learniaceutical composition for treatment of male 30

36. A method for reathern of a disorder selected from the group consisting of primary dysmenorrhoes pre-term labour, hypertension, Raynauld's

To see the second of the manufacture of the second of the

erectile dysfunction.

disease, brain occerna, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, lifer cirriosis and congestive heart failure which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound according to general formula 1, or a pharmaceutically acceptable salt thereof

wherein:

Empfangszeit 14:Reb

-G¹ is selected from a group according to general formula 2, a group according to general formula 3, a group according to general formula 4, a group according to general formula 5, a group according to general formula 6 and a group according to general formula 7;

- A is selected from CHIICH(OH), NHIN-alkyl, Q and S;
- A² is selected from CH₂ CH(OH), C(=0) and NH; A³ is selected from S, NH, N-alcyl, -OH=CH- and -CH=N-; A⁴ and A⁵ are each selected from CH and N;
- A⁶ is selected from CH, NH, N-alkyl and O; A⁷ and A¹¹ are selected from C and N;

 - A⁸ and A⁹ are selected from CH, N, NH, N(CH₂)_dR⁷ and S; A¹⁰ is selected from -CH=CH-CH, N NH, N(CH₂)_dR⁷ and S; A¹² and A¹³ are selected from N and C;
- A¹⁴, A¹⁵ and A are selected from NH, N-CH₃, S, N and CH;
 - X' is selected from O and NH;

 - R¹, R² and R³ are each selected from H. alkyl, O-alkyl, F, Cl and Br;
 R⁴ is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thinnyl, optionally substituted furyl, optionally substituted
- tuted pyridyl, optionally substituted pyrazolyl, optionally substituted pyrazolyl, optionally substituted im fazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, or ionally substituted thiazolyl, optionally substituted isothiazolyl, $-(CH_2)_cR^8$, CH_2 - CH_2 - CH_2 - CH_2 - R^8 , $-CH_2$ -C=C- CH_2 - R^8 , $-(CH_2)_g$ -

CH(OH)-(CH₂)₁-R⁸, -(CH₂)₁-O-(CH₂)₁-R and

- \mathbb{R}^5 and \mathbb{R}^6 are independently selected from alkyl, Ar and –(CH₂),–Ar;
 - R⁷ is selected from H, a kyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH₂, Nl alkyl, (alkyl)₂, NH-acyl, N(alkyl)-acyl, CO₂H, CO₂-alkyl, CONH₂, COl H-alkyl, CON alkyl)₂, CN and CF₃;
 R⁸ is selected from H, a kyl, alkenyl, a kynyl, acyl, optionally substituted phenyl, optionally substituted pyr dyl, optionally substituted thienyl, optionally
- . 25 substituted furyl, optionally substituted pyra-zolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxacolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, CH, hydroxyalkyl, O-acyl, S-alkyl, NH₂,
 - NH-alkyl, N(alkyl)2, 1-prolidingl, 1-pperidingl, 4-morpholingl, NH-acyl, N(alkyl)-acyl, N, CO₂H CO₂-allyl, CONH₂, CONH-alkyl, CON(alkyl)₂, CN and CF₃;
 - Ar is selected from optimally substituted thichyl and optionally substituted phenyl;

provided that:

- not more than one of A A and A is H, N(CH2)dR7 or S;

- A⁷ and A¹¹ are not both simultaneously

- neither A⁷ nor A¹¹ is N f one of A⁸, A and A¹⁰ is NH, N(CH₂)_dR⁷ or S;
- if A¹⁰ is not CH=CH—then one of A⁸, A⁹ and A¹⁰ is NH, N(CH₂)_dR⁷ or S or one of A^7 and A^1 is N;

- not more than one of A A A a A A A NH, N-CH3 or S;

- A¹² and A¹³ are not both simultaneous

- if one of A¹⁴, A¹⁵ and A¹⁶ is NIH V-CII, or S then A¹² and A¹³ are both C;

one of A¹⁴, A¹⁵ and A¹⁶ NH, CH₃ or S or one of A¹² and A¹³ is N.

37. The method of Claim 36, wherein at least one of R1, R2 and R3 is H and at least one is not H.

38. The inethod of Claim 56, wherein one of R¹, R² and R³ is selectifrom an alkyl group, an Galkyl group, If Cl and Br and the others are H. , wherein one of R1, R2 and R3 is selected

39. The inethod of Claim 10, wherein X is NH.

40. The method of Claim 10, wherein a is 1 and b is 2

41. The inethod of Claim is, wherein G is a group according to gen-25 eral formula 3.

42. The incthod of to Clair 41, whereinc is 2.

43. The incthed of Claim , whethin A is CH2 and A2 is NH.

44. The inethod of claim A, wherein A is NH or N-alkyl and A2 is C(≑0),

45. The thethod of Claim , wherein A is S and A and A are both

46. The method of Claim 11, wherein A3 is -CH=CH- and A4 and A5 are both CH.

5 47. The method of Claim 11, wherein A3 is -CH=N- and A4 and A5 are both CH.

48. The method of Claim 11, wherein A3 is -CH=CH-, A4 is CH and A5 is N.

49. The method of Claim 36, wherein G! is a group according to general formula 6 or 7

50. The inethod of Claim 49, wherein A³ is S and A⁴ and A⁵ are both

51. The method of Claim 19, wherein A³ is -CH=CH- and A⁴ and A⁵ are both CH.

52. The method of Claim 49, wherein A³ is -CH=N- and A⁴ and A⁵ are both CH.

53. The method of Claim 49, wherein A³ is -CH=CH-, A⁴ is CH and A⁵ is N.

54. The method of Claim $\S 6$, wherein \tilde{G}^1 is a group according to general formula 4 or 6.

55. The method of Claim 54, wherein A6 is NH.

56. The method of Claim 34, wherein A8 is NH or N+(CH₂)_d-R⁷.

57. The method of Claim 56, wherein A9 is N and A10 is CH.

3 5

20

to that the troop of Additional and Application of Section 11 of the Section 12 of the Application of the Ap

- 58. The method of Claim 66, wherein one of R, R² and R³ is selected from an alkyl group, an Chalkyl group, E, Cl and Br and the others are H and X' is NH.
- 59. The method of Claim 30, wherein one of R1, R2 and R3 is selected from an alkyl group, an Chalkyl group, All Cl and Br and the others are H and X1 is NH, a is 1 and b is
- 60. The method of Claim 6, wherein G1 is a group according to general formula 6, A4, A and A1 are all CH, A6 is NH, A7 and A11 are both C, A8 is N-(CH₂)_d-R⁷ and A⁹ is N
- 61. The method of Claim So, wherein R¹ is an alkyl group, an O-alkyl group, F, Cl or Br, R² and R are both H, K¹ is NH, a is 1, b is 2, G¹ is a group according to general formula 6, A^4 , A^5 and A^{10} are all CH; A^6 is NH, A^7 and A^{11} are both C, A^8 is N-(CH₂)_d-R and A^{11} is N.
 - 62. The method of Claim gd, wherein said compound is selected from the group consisting of:
- 4-Cyclopropylmethyl-piperazine 1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-31-2,3,4,9-etraazine penzo fijazulene-9-carbonyl)-benzylamide,
 - - 4-(3,3-Dimethyl-butyl) iperazine-1-carboxylic acid 2-methyl-4-(3-methyl-
 - 4,10-dihydro-3,42,3,4,9 etraaz benzo hazulene-9-carbonyl)-benzylamide,
 - 4-(3-Methylsulfanyl-prinyl)-priperazine 1-carboxylic acid 2-methyl-4-(3-
 - methyl-4,10-dilydro-3H, 3,4,9 ctrazza benzo[f]azulene-9-carbonyl)benzylamide,
 - 4-(2-Cyclopropy) ethyl pipera inc-1-carboxylic acid 2-methyl-4-(3-methyl-
 - 4,10-dihydro-31-1-2,3,4,9 tettaaz benzo fazulene-9-carbonyl)-benzylamide,
 - 4-Cyclopropyl nethyl-proejazia 1-can oxylic acid 3-methyl-4-(3-methyl-
- 4,10-dihydro 31-12,3,4,9 remazzi benzoli jazulene-9-carbonyl)-benzylamide,
 4-Cyclopropyl hethyl-pherazi c-1-carboxylic acid 3-fluoro-4-(3-methyl-
 - _4,10-dillydro-31-2,3,4,9 ctranz benzofflazulene-9-carbonyl)-benzylamide,
 - 4-(2-Hydroxynethyl-cycloprogymethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10 dillydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-
- carbonyl)-benzylamide,

٥

- 4-(3-Methyl-butyl)-pip azine-li-carboxylic acid 2-methyl-4-(3-methyl-4, 10 dilydro-3H-2,3,4,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide,
-4-Cyclopentylinethyl-pherazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-311-2,3,4,9 tetraazi benzolijazulene-9-carbonyl)-benzylainide. - 4-Cyclohexylinethyl-pigerazini-l-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3!11-2,3,4,9 tetraazil benzollijazulene-9-carbonyl)-benzylamide, - 4-Cyclopropy thethyl-pperazite I-carpoxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3142,3,4,9 etraaz benzo bazulene-9-carbonyl)-benzylamide, - 4-Cyclobutylinethyl-piperazine l-carbaxylic acid 3-chloro-4-(3-methyl-4,10dihydro-3H-2,34,9-tetra za-benzo[f]azulene-9-carbonyl)-benzylamide,
-4-Cyclobutylinethyl-pinerazine 1-carboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9 tetra za-benzo[f]azwene-9-carbonyl)-benzylamide,
-4-(2-Cyclopropyl-ethyl piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraazi-benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Pentyl-piperazine-1-cirboxylic acid 2-methyl-4-(3-methyl-4,10-dibydro-3H-2,3,4,9-ten azine-1-cirboxylic acid 2-methyl-4-(3-methyl-4,10-dibydro-3H-2,1 15 - 4-Hexyl-piperazine-1-cerboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-terraza-benze [f]azulenc-9-carbonyl)-benzylamide, - (R)-4-(2-Methyl-butyl) piperazine-1-chiboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3-12,3,4,9 etraaz penzo fjazulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piper zine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9 tetra za-benzo [f]azu ene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyla piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 etraaza benzo [jazulene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-piperazine 1 carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraaga-benzo[f]azulenc-9-carbonyl)-benzylamide, - 4-Cyclobutylinicthyl-piperazine 1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2|3|4,9 tetraava-benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclobuty In ethyl-pinerazine il carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetra za-benzo f]azulene-9-carbonyl)-benzylamide. - 4-Cyclopropylmethyl-procrazing 1-carboxylic acid 2-fluoro-4-(3-methyl 4,10-dihydro-3 H 2,3,4,9-etraaza tenzo hazulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine u carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzal fjazulene-9-carbonyl)-benzylamide.
- 4-Cyclopropy niethyl-procrazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzol fjazulene-9-carbonyl)-benzylamide,

And the last 15 48 V 14 Colombia and the last th

Empfansszeit 14-Feb. 16:14

- 4-Cyclobutylmethyl-piperazing l-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetradza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylinethyl-piperazine 1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraazil benzolfjazulene-9-carbonyl)-benzylamide,
and

- 4-Cyclobutylinethyl-piperazine l-carbaxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3ii-12,3,4,9 etraazi-benzolfilazulene-9-carbonyl)-benzylamide.

63. A inethol for leatment of male erectile dysfunction which comprises the administration a person in need of such treatment of therapeuti-10 cally effective amount offa compound selected from the group consisting of:
- 4-(3,3-Dimetily-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-311-2,3,4,9 tetraazi benzo jazulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-311.2,3,4,9 etraaza penzo fazulene-9-carbonyl)-benzylamide. - 4-Cyclopropylmethyl-pperazine 1-campxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3,1,2,3,4,9 etrazz benzo pazulene-9-carbonyl)-benzylamide, - 4-Cyclopropylmethyl-p perazine 1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 etraaza-penzo[[]azulene-9-carbonyl)-benzylamide, - 4-(2-Hydroxymethyl-cycloprojymethyl)-piperazine-1-carboxylic acid 2 methyl-4-(3-methyl-4,10 dihydr 3H-2,34,9-tetraaza-benzo[f]azulenc-9carbonyl)-benzylamide, - 4-(3-Methyl-butyl)-pip fazine- carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-bengo[1]azu ene-9-carbonyl)-benzylamide, - 4-Cyclopentylmethyl-piperazing-ll-carboxylic acid 2-methyl-4-(3-methyl-4,10-diliydro-31,1-2,3,4,9-etraaza benzo[flazulene-9-carbonyl]-benzylamide,
- 4-Cyclohexylmethyl-piperazing-l-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3112,3,4,9-etraazaf lenzo[fazulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-pherazine 1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3112,3,4,9-etraazi benzol azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-pip razine learboxylic acid 3-chloro-4-(3-methyl-4,10dihydro-3H-2,3,4,9 tetrugen-benic [f]uzulenc-9 carbonyl)-benzylamide, - 4-Cyclobutylinethyl-pinerazine l-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetrasza-benzo fjazulene-9-carbonyl)-benzylamide. - 4-(2-Cyclopropyl-ethyl) piperague-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-31-2,3,4,9-traazattenzo[[[azulenc-9-carbonyl]-benzylamide,

The state of battleman were made to the time of the continue of the continue of

5

98

- 4-Pentyl-piperazine-1-carboxy acid 2 methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-temaizh-benze [f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-pipe azine-1-carboxyl cacid 2 methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetradza benze [f]azu enc-9-carbonyl)-benzylamide, - (R)-4-(2-Methyl-butyl) piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 etraazi-benzo fjazulene-9-carbonyl)-benzylamide, - 4-(2-Ethyl-butyl)-piper zine-1 carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetra za-benzo[f]azulene-9-carbonyl)-benzylamide. - 4-(2-Methyl-but-2-enyli-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraazz-benzo fjazulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10--dihydro-3H-2,3,4,9 tetra za-benzo[f]azu enc-9-carbonyl)-benzylamide,
- 4-Cycloburylinethyl-piperazine-1-carboxylic acid-3-fluoro-4-(3-methyl-4,10dihydro-3H-2,3,4,9-tetra za-benzo[f]azu enc-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-piperazine - carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetra za-benzo[f]azulene-9-carbonyl)-benzylamide, - 4-Cyclopropylme hyl-piperazite-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 tetraazi-benzo []azulene-9-carbonyl)-benzylamide. - 4-Cyclobutylinethyl-pijjerazine | -carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza benze [f]azu ene-9-carbonyl)-benzylamide,
- 4-Cyclopropylate hyl-1 perazite-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10dihydro-3H-2,3,4,9 tetra za-ben o[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylinethyl-piperazine 1-carboxylic acid 2-chloro-4-(3-methyl-4,10dihydro-3H-2,3,4,9 tetra za-benze[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylinethyl-pperazine-1-canboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3112,3,4,9 etraaz benzolijazulene-9-carbonyl)-benzylamide, - 4-Cyclobutylmethyl-pijrerazine I-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9 etraazi benzolijazulene-9-carbonyl)-benzylamide; pharmaceutically acceptable sale of the bove mentioned compounds.

ABSTRACT

Novel compounds according to general formula 1, wherein G¹ is NR⁵R⁶ or a fixed polycyclic group that are specific OT receptor agonists and/or V_{1a} receptor antagonists. Phalmaceurcal compositions comprising such compounds are useful in the teatment of, inter alia, primary dysmenorrhoea.

$$R^{1}$$
 R^{2}
 $N - R$
 $(CH_{2})_{a}$
 $N - R$

The character of the state of t

Empfansszeit 14. Feb. 16:14

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.